Pharmaceutical compositions containing exendins

ABSTRACT

Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.

This application claims the benefit of U.S. Provisional Application No.60/034,905, filed Jan. 7, 1997, U.S. Provisional Application No.60/055,404, filed Aug. 8, 1997, U.S. Provisional Application No.60/066,029 filed Nov. 14, 1997, and U.S. Provisional Application No.60/065,442, Nov. 14, 1997.

FIELD OF THE INVENTION

The present invention relates to methods for treating conditions ordisorders which can be alleviated by reducing food intake comprisingadministration of an effective amount of an exendin or an exendinagonist alone or in conjunction with other compounds or compositionsthat affect satiety such as a leptin or an amylin agonist. The methodsare useful for treating conditions or disorders, in which the reductionof food intake is of value, including obesity, Type II diabetes, eatingdisorders, and insulin-resistance syndrome. The methods are also usefulfor lowering the plasma lipid level, reducing the cardiac risk, reducingthe appetite, and reducing the weight of subjects. Pharmaceuticalcompositions for use in the methods of the invention are also disclosed.

BACKGROUND

The following description summarizes information relevant to the presentinvention. It is not an admission that any of the information providedherein is prior art to the presently claimed invention, nor that any ofthe publications specifically or implicitly referenced are prior art tothat invention.

Exendin

Exendins are peptides that are found in the venom of the Gila-monster, alizard found in Arizona, and the Mexican Beaded Lizard. Exendin-3 ispresent in the venom of Heloderma horridum, and exendin-4 is present inthe venom of Heloderma suspectum (Eng, J., et al., J. Biol. Chem.,265:20259-62, 1990; Eng., J., et al., J. Biol. Chem., 267:7402-05,1992). The exendins have some sequence similarity to several members ofthe glucagon-like peptide family, with the highest homology, 53%, beingto GLP-1[7-36]NH₂ (Goke, et al., J. Biol. Chem., 268:19650-55, 1993).GLP-1[7-36]NH₂, also known as proglucagon [78-107], has aninsulinotropic effect, stimulating insulin secretion from pancreaticβ-cells; GLP also inhibits glucagon secretion from pancreatic α-cells(Orskov, et al., Diabetes, 42:658-61, 1993; D'Alessio, et al., J. Clin.Invest., 97:133-38, 1996). GLP-1 is reported to inhibit gastric emptying(Williams B, et al., J Clin Endocrinol Metab 81 (1): 327-32, 1996;Wettergren A, et al., Dig Dis Sci 38 (4): 665-73, 1993), and gastricacid secretion. (Schjoldager B T, et al., Dig Dis Sci 34 (5): 703-8,1989; O'Halloran D J, et al., J Endocrinol 126 (1): 169-73, 1990;Wettergren A, et al., Dig Dis Sci 38 (4): 665-73, 1993). GLP-1[7-37],which has an additional glycine residue at its carboxy terminus, alsostimulates insulin secretion in humans (Orskov, et al., Diabetes,42:658-61, 1993). A transmembrane G-protein adenylate-cyclase-coupledreceptor believed to be responsible for the insulinotropic effect ofGLP-1 is reported to have been cloned from a β-cell line (Thorens, Proc.Natl. Acad. Sci. USA 89:8641-45 (1992)).

Exendin-4 potently binds at GLP-1 receptors on insulin-secreting βTC1cells, at dispersed acinar cells from guinea pig pancreas, and atparietal cells from stomach; the peptide is also said to stimulatesomatostatin release and inhibit gastrin release in isolated stomachs(Goke, et al., J. Biol. Chem. 268:19650-55, 1993; Schepp, et al., Eur.J. Pharmacol., 69:183-91, 1994; Eissele, et al., Life Sci., 55:629-34,1994). Exendin-3 and exendin-4 were reported to stimulate cAMPproduction in, and amylase release from, pancreatic acinar cells(Malhotra, R., et al., Regulatory Peptides, 41:149-56, 1992; Raufman, etal., J. Biol. Chem. 267:21432-37, 1992; Singh, et al., Regul. Pept.53:47-59, 1994). The use of exendin-3 and exendin-4 as insulinotrophicagents for the treatment of diabetes mellitus and the prevention ofhyperglycemia has been proposed (Eng, U.S. Pat. No. 5,424,286).

C-terminally truncated exendin peptides such as exendin[9-39], acarboxyamidated molecule, and fragments 3-39 through 9-39 have beenreported to be potent and selective antagonists of GLP-1 (Goke, et al.,J. Biol. Chem., 268:19650-55, 1993; Raufman, J. P., et al., J. Biol.Chem. 266:2897-902, 1991; Schepp, W., et al., Eur. J. Pharm. 269:183-91,1994; Montrose-Rafizadeh, et al., Diabetes, 45(Suppl. 2):152A, 1996).Exendin[9-39] is said to block endogenous GLP-1 in vivo, resulting inreduced insulin secretion. Wang, et al., J. Clin. Invest., 95:417-21,1995; D'Alessio, et al., J. Clin. Invest., 97:133-38, 1996). Thereceptor apparently responsible for the insulinotropic effect of GLP-1has reportedly been cloned from rat pancreatic islet cell (Thorens, B.,Proc. Natl. Acad. Sci. USA 89:8641-8645, 1992). Exendins andexendin[9-39] are said to bind to the cloned GLP-1 receptor (ratpancreatic β-cell GLP-1 receptor (Fehmann H C, et al., Peptides 15 (3):453-6, 1994) and human GLP-1 receptor (Thorens B, et al., Diabetes 42(11): 1678-82, 1993). In cells transfected with the cloned GLP-1receptor, exendin-4 is reportedly an agonist, i.e., it increases cAMP,while exendin[9-39] is identified as an antagonist, i.e., it blocks thestimulatory actions of exendin-4 and GLP-1. Id.

Exendin[9-39] is also reported to act as an antagonist of the fulllength exendins, inhibiting stimulation of pancreatic acinar cells byexendin-3 and exendin-4 (Raufman, et al., J. Biol. Chem. 266:2897-902,1991; Raufman, et al., J. Biol. Chem., 266:21432-37, 1992). It is alsoreported that exendin[9-39] inhibits the stimulation of plasma insulinlevels by exendin-4, and inhibits the somatostatin release-stimulatingand gastrin release-inhibiting activities of exendin-4 and GLP-1(Kolligs, F., et al., Diabetes, 44:16-19, 1995; Eissele, et al., LifeSciences, 55:629-34, 1994).

Exendins have recently been found to inhibit gastric emptying (U.S. Ser.No. 08/694,954, filed Aug. 8, 1996, which enjoys common ownership withthe present invention and is hereby incorporated by reference).

Exendin [9-39] has been used to investigate the physiological relevanceof central GLP-1 in control of food intake (Turton, M. D. et al. Nature379:69-72, 1996). GLP-1 administered by intracerebroventricularinjection inhibits food intake in rats. This satiety-inducing effect ofGLP-1 delivered ICV is reported to be inhibited by ICV injection ofexendin [9-39] (Turton, supra). However, it has been reported that GLP-1does not inhibit food intake in mice when administered by peripheralinjection (Turton, M. D., Nature 379:69-72, 1996; Bhavsar, S. P., Soc.Neurosci. Abstr. 21:460 (188.8), 1995).

Obesity and Hypernutrition

Obesity, excess adipose tissue, is becoming increasingly prevalent indeveloped societies. For example, approximately 30% of adults in theU.S. were estimated to be 20 percent above desirable body weight—anaccepted measure of obesity sufficient to impact a health risk(Harrison's Principles of Internal Medicine 12th Edition, McGraw Hill,Inc. (1991) p. 411). The pathogenesis of obesity is believed to bemultifactorial but the basic problem is that in obese subjects foodintake and energy expenditure do not come into balance until there isexcess adipose tissue. Attempts to reduce food intake, orhypernutrition, are usually fruitless in the medium term because theweight loss induced by dieting results in both increased appetite anddecreased energy expenditure (Leibel et al., (1995) New England Journalof Medicine 322: 621-628). The intensity of physical exercise requiredto expend enough energy to materially lose adipose mass is too great formost people to undertake on a sufficiently frequent basis. Thus, obesityis currently a poorly treatable, chronic, essentially intractablemetabolic disorder. Not only is obesity itself believed by some to beundesirable for cosmetic reasons, but obesity also carries serious riskof co-morbidities including, Type 2 diabetes, increased cardiac risk,hypertension, atherosclerosis, degenerative arthritis, and increasedincidence of complications of surgery involving general anesthesiaobesity due to hypernutrition is also a risk factor for the group ofconditions called insulin resistance syndrome, or “syndrome X.” Insyndrome X, it has been reported that there is a linkage between insulinresistance and hypertension. (Watson N. and Sandler M., Curr. Med. Res.Opin., 12(6):374-378 (1991); Kodama J. et al., Diabetes Care,13(11):1109-1111 (1990); Lithell et al., J. Cardiovasc. Pharmacol., 15Suppl. 5:S46-S52 (1990)).

In those few subjects who do succeed in losing weight, by about 10percent of body weight, there can be striking improvements in co-morbidconditions, most especially Type 2 diabetes in which dieting and weightloss are the primary therapeutic modality, albeit relatively ineffectivein many patients for the reasons stated above. Reducing food intake inobese subjects would decrease the plasma glucose level, the plasma lipidlevel, and the cardiac risk in these subjects. Hypernutrition is alsothe result of, and the psychological cause of, many eating disorders.Reducing food intake would also be beneficial in the treatment of suchdisorders.

Thus, it can be appreciated that an effective means to reduce foodintake is a major challenge and a superior method of treatment would beof great utility. Such a method, and compounds and compositions whichare useful therefor, have been invented and are described and claimedherein.

SUMMARY OF THE INVENTION

The present invention concerns the surprising discovery that exendinsand exendin agonists have a profound and prolonged effect on inhibitingfood intake.

The present invention is directed to novel methods for treatingconditions or disorders associated with hypernutrition, comprising theadministration of an exendin, for example, exendin-3 [SEQ ID NO. 1: HisSer Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala ValArg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro ProPro Ser], or exendin-4 [SEQ ID NO. 2: His Gly Glu Gly Thr Phe Thr SerAsp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp LeuLys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser], or other compoundswhich effectively bind to the receptor at which exendin exerts itsaction on reducing food intake. These methods will be useful in thetreatment of, for example, obesity, diabetes, including Type II ornon-insulin dependent diabetes, eating disorders, and insulin-resistancesyndrome.

In a first aspect, the invention features a method of treatingconditions or disorders which can be alleviated by reducing food intakein a subject comprising administering to the subject a therapeuticallyeffective amount of an exendin or an exendin agonist. By an “exendinagonist” is meant a compound that mimics the effects of exendin on thereduction of food intake by binding to the receptor or receptors whereexendin causes this effect. Preferred exendin agonist compounds includethose described in U.S. Provisional Patent Application Ser. No.60/055,404, entitled, “Novel Exendin Agonist Compounds,” filed Aug. 8,1997; U.S. Provisional Patent Application Ser. No. 60/065,442, entitled,“Novel Exendin Agonist Compounds,” filed Nov. 14, 1997; and U.S.Provisional Patent Application Ser. No. 60/066,029, entitled, “NovelExendin Agonist Compounds,” filed Nov. 14, 1997; all of which enjoycommon ownership with the present application and all of which areincorporated by this reference into the present application as thoughfully set forth herein. By “condition or disorder which can bealleviated by reducing food intake” is meant any condition or disorderin a subject that is either caused by, complicated by, or aggravated bya relatively high food intake, or that can be alleviated by reducingfood intake. Such conditions or disorders include, but are not limitedto, obesity, diabetes, including Type II diabetes, eating disorders, andinsulin-resistance syndrome.

Thus, in a first embodiment, the present invention provides a method fortreating conditions or disorders which can be alleviated by reducingfood intake in a subject comprising administering to said subject atherapeutically effective amount of an exendin or an exendin agonist.Preferred exendin agonist compounds include those described in U.S.Provisional Patent Application Ser. Nos. 60/055,404; 60/065,442; and60/066,029, which have been incorporated by reference in the presentapplication. Preferably, the subject is a vertebrate, more preferably amammal, and most preferably a human. In preferred aspects, the exendinor exendin agonist is administered parenterally, more preferably byinjection. In a most preferred aspect, the injection is a peripheralinjection. Preferably, about 10 μg-30 μg to about 5 mg of the exendin orexendin agonist is administered per day. More preferably, about 10-30 μgto about 2 mg, or about 10-30 μg to about 1 mg of the exendin or exendinagonist is administered per day. Most preferably, about 30 μg to about500 μg of the exendin or exendin agonist is administered per day.

In various preferred embodiments of the invention, the condition ordisorder is obesity, diabetes, preferably Type II diabetes, an eatingdisorder, or insulin-resistance syndrome.

In other preferred aspects of the invention, a method is provided forreducing the appetite of a subject comprising administering to saidsubject an appetite-lowering amount of an exendin or an exendin agonist.

In yet other preferred aspects, a method is provided for lowering plasmalipids comprising administering to said subject a therapeuticallyeffective amount of an exendin or an exendin agonist.

The methods of the present invention may also be used to reduce thecardiac risk of a subject comprising administering to said subject atherapeutically effective amount of an exendin or an exendin agonist. Inone preferred aspect, the exendin or exendin agonist used in the methodsof the present invention is exendin-3. In another preferred aspect, saidexendin is exendin-4. Other preferred exendin agonists include exendin-4(1-30) [SEQ ID NO 6: His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly],exendin-4 (1-30) amide [SEQ ID NO 7: His Gly Glu Gly Thr Phe Thr Ser AspLeu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu LysAsn Gly Gly-NH₂], exendin-4 (1-28) amide [SEQ ID NO 40: His Gly Glu GlyThr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu PheIle Glu Trp Leu Lys Asn-NH₂], ¹⁴Leu,²⁵Phe exendin-4 amide [SEQ ID NO 9:His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu AlaVal Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala ProPro Pro Ser-NH₂], ¹⁴Leu, ²⁵Phe exendin-4 (1-28) amide [SEQ ID NO 41: HisGly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala ValArg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂], and ¹⁴Leu, ²²Ala,²⁵Pheexendin-4 (1-28) amide [SEQ ID NO 8: His Gly Glu Gly Thr Phe Thr Ser AspLeu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Ala Ile Glu Phe Leu LysAsn-NH₂].

In the methods of the present invention, the exendins and exendinagonists may be administered separately or together with one or moreother compounds and compositions that exhibit a long term or short-termsatiety action, including, but not limited to other compounds andcompositions that comprise an amylin agonist, cholecystokinin (CCK), ora leptin (ob protein). Suitable amylin agonists include, for example,[^(25,28,29)Pro-]-human amylin (also known as “pramlintide,” andpreviously referred to as “AC-137”) as described in “Amylin AgonistPeptides and Uses Therefor,” U.S. Pat. No. 5,686,511, issued Nov. 11,1997, and salmon calcitonin. The CCK used is preferably CCK octopeptide(CCK-8). Leptin is discussed in, for example, Pelleymounter, M. A., etal. Science 269:540-43 (1995); Halaas, J. L., et al. Science 269:543-46(1995); and Campfield, L. A., et al. Eur. J. Pharmac. 262:133-41 (1994).

In other embodiments of the invention is provided a pharmaceuticalcomposition for use in the treatment of conditions or disorders whichcan be alleviated by reducing food intake comprising a therapeuticallyeffective amount of an exendin or exendin agonist in association with apharmaceutically acceptable carrier. Preferably, the pharmaceuticalcomposition comprises a therapeutically effective amount for a humansubject.

The pharmaceutical composition may preferably be used for reducing theappetite of a subject, reducing the weight of a subject, lowering theplasma lipid level of a subject, or reducing the cardiac risk of asubject. Those of skill in the art will recognize that thepharmaceutical composition will preferably comprise a therapeuticallyeffective amount of an exendin or exendin agonist to accomplish thedesired effect in the subject.

The pharmaceutical compositions may further comprise one or more othercompounds and compositions that exhibit a long-term or short-termsatiety action, including, but not limited to other compounds andcompositions that comprise an amylin agonist, CCK, preferably CCK-8, orleptin. Suitable amylin agonists include, for example,[^(25,28,29)Pro]-human amylin and salmon calcitonin.

In one preferred aspect, the pharmaceutical composition comprisesexendin-3. In another preferred aspect, the pharmaceutical compositioncomprises exendin-4. In other preferred aspects, the pharmaceuticalcompositions comprises a peptide selected from: exendin-4 (1-30),exendin-4 (1-30) amide, exendin-4 (1-28) amide, ¹⁴Leu,²⁵Phe exendin-4amide, ¹⁴Leu,²⁵Phe exendin-4 (1-28) amide, and ¹⁴Leu ,²²Ala,²⁵Pheexendin-4 (1-28) amide.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graphical depiction of the change of food intake in normalmice after intraperitoneal injection of exendin-4 and GLP-1.

FIG. 2 is a graphical depiction of the change of food intake in obesemice after intraperitoneal injection of exendin-4.

FIG. 3 is a graphical depiction of the change of food intake in ratsafter intracerebroventricular injection of exendin-4

FIG. 4 is a graphical depiction of the change of food intake in normalmice after intraperitoneal injection of exendin-4 (1-30) (“Compound 1”).

FIG. 5 is a graphical depiction of the change of food intake in normalmice after intraperitoneal injection of exendin-4 (1-30) amide(“Compound 2”).

FIG. 6 is a graphical depiction of the change of food intake in normalmice after intraperitoneal injection of exendin-4 (1-28) amide(“Compound 3”).

FIG. 7 is a graphical depiction of the change of food intake in normalmice after intraperitoneal injection of ¹⁴Leu,²⁵Phe exendin4 amide(“Compound 4”).

FIG. 8 is a graphical depiction of the change of food intake in normalmice after intraperitoneal injection of ¹⁴Leu,²⁵Phe exendin-4 (1-28)amide (“Compound 5”).

FIG. 9 is a graphical depiction of the change of food intake in normalmice after intraperitoneal injection of ¹⁴Leu,²²Ala,²⁵Phe exendin-4(1-28) amide (“Compound 6”).

FIG. 10 depicts the amino acid sequences for certain exendin agonistcompounds useful in the present invention [SEQ ID NOS 9-39].

DETAILED DESCRIPTION OF THE INVENTION

Exendins and exendin agonists are useful as described herein in view oftheir pharmacological properties. Activity as exendin agonists can beindicated by activity in the assays described below. Effects of exendinsor exendin agonists on reducing food intake can be identified,evaluated, or screened for, using the methods described in the Examplesbelow, or other methods known in the art for determining effects on foodintake or appetite.

Exendin Agonist Compounds

Exendin agonist compounds are those described in U.S. ProvisionalApplication No. 60/055,404, including compounds of the formula (I) [SEQID NO. 3]:  1                  5                      10 Xaa₁ Xaa₂ Xaa₃Gly Thr Xaa₄ Xaa₅ Xaa₆ Xaa₇ Xaa₈                  15                  20Ser Lys Gln Xaa₉ Glu Glu Glu Ala Val Arg Leu                  25                      30 Xaa₁₀ Xaa₁₁ Xaa₁₂ Xaa₁₃ LeuLys Asn Gly Gly Xaa₁₄             35 Ser Ser Gly Ala Xaa₁₅ Xaa₁₆ Xaa₁₇Xaa₁₈-Zwherein Xaa₁ is His, Arg or Tyr; Xaa₂ is Ser, Gly, Ala or Thr; Xaa₃ isAsp or Glu; Xaa₄ is Phe, Tyr or naphthylalanine; Xaa, is Thr or Ser;Xaa₆ is Ser or Thr; Xaa₇ is Asp or Glu; Xaa₈ is Leu, Ile, Val,pentylglycine or Met; Xaa₉ is Leu, Ile, pentylglycine, Val or Met; Xaa₁₀is Phe, Tyr or naphthylalanine; Xaa₁₁ is Ile, Val, Leu, pentylglycine,tert-butylglycine or Met; Xaa₁₂ is Glu or Asp; Xaa₁₃ is Trp, Phe, Tyr,or naphthylalanine; Xaa₁₄, Xaa₁₅, Xaa₁₆ and Xaa₁₇ are independently Pro,homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine,N-alkylpentylglycine or N-alkylalanine; Xaa₁₈ is Ser, Thr or Tyr; and Zis —OH or —NH₂; with the proviso that the compound is not exendin-3 orexindin-4.

Preferred N-alkyl groups for N-alkylglycine, N-alkylpentylglycine andN-alkylalanine include lower alkyl groups preferably of 1 to about 6carbon atoms, more preferably of 1 to 4 carbon atoms. Suitable compoundsinclude those listed in FIG. 10 having amino acid sequences of SEQ. ID.NOS. 9 to 39.

Preferred exendin agonist compounds include those wherein Xaa₁ is His orTyr. More preferably Xaa₁ is His.

Preferred are those compounds wherein Xaa₂ is Gly.

Preferred are those compounds wherein Xaa₉ is Leu, pentylglycine or Met.

Preferred compounds include those wherein Xaa₁₃ is Trp or Phe.

Also preferred are compounds where Xaa₄ is Phe or naphthylalanine; Xaa₁₁is Ile or Val and Xaa₁₄, Xaa₁₅, Xaa₁₆ and Xaa₁₇ are independentlyselected from Pro, homoproline, thioproline or N-alkylalanine.Preferably N-alkylalanine has a N-alkyl group of 1 to about 6 carbonatoms.

According to an especially preferred aspect, Xaa₁₅, Xaa₁₆ and Xaa₁₇ arethe same amino acid reside.

Preferred are compounds wherein Xaa₁₈ is Ser or Tyr, more preferablySer.

Preferably Z is —NH₂.

According to one aspect, preferred are compounds of formula (I) whereinXaa₁ is His or Tyr, more preferably His; Xaa₂ is Gly; Xaa₄ is Phe ornaphthylalanine; Xaa₉ is Leu, pentylglycine or Met; Xaa₁₀ is Phe ornaphthylalanine; Xaa₁₁ is Ile or Val; Xaa₁₄, Xaa₁₅, Xaa₁₆ and Xaa₁₇ areindependently selected from Pro, homoproline, thioproline orN-alkylalanine; and Xaa₁₈ is Ser or Tyr, more preferably Ser. Morepreferably Z is —NH₂.

According to an especially preferred aspect, especially preferredcompounds include those of formula (I) wherein: Xaa₁ is His or Arg; Xaa₂is Gly; Xaa₃ is Asp or Glu; Xaa₄ is Phe or napthylalanine; Xaa₅ is Thror Ser; Xaa₆ is Ser or Thr; Xaa₇ is Asp or Glu; Xaa₈ is Leu orpentylglycine; Xaa₉ is Leu or pentylglycine; Xaa₁₀ is Phe ornaphthylalanine; Xaa₁₁ is Ile, Val or t-butyltylglycine; Xaa₁₂ is Glu orAsp; Xaa₁₃ is Trp or Phe; Xaa₁₄, Xaa₁₅, Xaa₁₆, and Xaa₁₇ areindependently Pro, homoproline, thioproline, or N-methylalanine; Xaa₁₈is Ser or Tyr: and Z is —OH or —NH₂; with the proviso that the compounddoes not have the formula of either SEQ. ID. NOS. 1 or 2. Morepreferably Z is —NH₂. Especially preferred compounds include thosehaving the amino acid sequence of SEQ. ID. NOS. 9, 10, 21, 22, 23, 26,28, 34, 35 and 39.

According to an especially preferred aspect, provided are compoundswhere Xaa₉ is Leu, Ile, Val or pentylglycine, more preferably Leu orpentylglycine, and Xaa₁₃ is Phe, Tyr or naphthylalanine, more preferablyPhe or naphthylalanine. These compounds will exhibit advantageousduration of action and be less subject to oxidative degration, both invitro and in vivo, as well as during synthesis of the compound.

Exendin agonist compounds also include those described in U.S.Provisional Application No. 60/065,442, including compounds of theformula (II) [SEQ ID NO. 4]: Xaa₁ Xaa₂ Xaa₃ Gly Xaa₅ Xaa₆ Xaa₇ Xaa₈ Xaa₉Xaa₁₀ Xaa₁₁ Xaa₁₂ Xaa₁₃ Xaa₁₄ Xaa₁₅ Xaa₁₆ Xaa₁₇ Ala Xaa₁₉ Xaa₂₀ Xaa₂₁Xaa₂₂ Xaa₂₃ Xaa₂₄ Xaa₂₅ Xaa₂₆ Xaa₂₇ Xaa₂₈-Z₁;wherein

-   -   Xaa₁ is His, Arg or Tyr;    -   Xaa₂ is Ser, Gly, Ala or Thr;    -   Xaa₃ is Asp or Glu;    -   Xaa₅ is Ala or Thr;    -   Xaa₆ is Ala, Phe, Tyr or naphthylalanine;    -   Xaa₇ is Thr or Ser;    -   Xaa₈ is Ala, Ser or Thr;    -   Xaa₉ is Asp or Glu;    -   Xaa₁₀ is Ala, Leu, Ile, Val, pentylglycine or Met;    -   Xaa₁₁ is Ala or Ser;    -   Xaa₁₂ is Ala or Lys;    -   Xaa₁₃ is Ala or Gln;    -   Xaa₁₄ is Ala, Leu, Ile, pentylglycine, Val or Met;    -   Xaa₁₅ is Ala or Glu;    -   Xaa₁₆ is Ala or Glu;    -   Xaa₁₇ is Ala or Glu;    -   Xaa₁₉ is Ala or Val;    -   Xaa₂₀ is Ala or Arg;    -   Xaa₂₁ is Ala or Leu;    -   Xaa₂₂ is Ala, Phe, Tyr or naphthylalanine;    -   Xaa₂₃ is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met;    -   Xaa₂₄ is Ala, Glu or Asp;    -   Xaa₂₅ is Ala, Trp, Phe, Tyr or naphthylalanine;    -   Xaa₂₆ is Ala or Leu;    -   Xaa₂₇ is Ala or Lys;    -   Xaa₂₈ is Ala or Asn;    -   Z₁ is —OH,        -   —NH₂        -   Gly-Z₂,        -   Gly Gly-Z₂,        -   Gly Gly Xaa₃₁-Z₂,        -   Gly Gly Xaa₃₁ Ser-Z₂,        -   Gly Gly Xaa₃₁ Ser Ser-Z₂,        -   Gly Gly Xaa₃₁ Ser Ser Gly-Z₂,        -   Gly Gly Xaa₃₁ Ser Ser Gly Ala-Z₂,        -   Gly Gly Xaa₃₁ Ser Ser Gly Ala Xaa₃₆-Z₂,        -   Gly Gly Xaa₃₁ Ser Ser Gly Ala Xaa₃₆ Xaa₃₇-Z₂ or        -   Gly Gly Xaa₃₁ Ser Ser Gly Ala Xaa₃₆ Xaa₃₇ Xaa₃₈-Z₂;        -   Xaa₃₁, Xaa₃₆, Xaa₃₇ and Xaa₃₈ are independently Pro,            homoproline, 3Hyp, 4Hyp, thioproline,        -   N-alkylglycine, N-alkylpentylglycine or        -   N-alkylalanine; and        -   Z₂ is —OH or —NH₂;            provided that no more than three of Xaa₃, Xaa₅, Xaa₆, Xaa₈,            Xaa₁₀, Xaa₁₁, Xaa₁₂, Xaa₁₃, Xaa₁₄, Xaa₁₅, Xaa₁₆, Xaa₁₇,            Xaa₁₉, Xaa₂₀, Xaa₂₁, Xaa₂₄, Xaa₂₅, Xaa₂₆, Xaa₂₇ and Xaa₂₈            are Ala. Preferred N-alkyl groups for N-alkylglycine,            N-alkylpentylglycine and N-alkylalanine include lower alkyl            groups preferably of 1 to about 6 carbon atoms, more            preferably of 1 to 4 carbon atoms.

Preferred exendin agonist compounds include those wherein Xaa₁ is His orTyr. More preferably Xaa₁ is His.

Preferred are those compounds wherein Xaa₂ is Gly.

Preferred are those compounds wherein Xaa₁₄ is Leu, pentylglycine orMet.

Preferred compounds are those wherein Xaa₂, is Trp or Phe.

Preferred compounds are those where Xaa₆ is Phe or naphthylalanine;Xaa₂₂ is Phe or naphthylalanine and Xaa₂₃ is Ile or Val.

Preferred are compounds wherein Xaa₃₁, Xaa₃₆, Xaa₃₇ and Xaa₃₈ areindependently selected from Pro, homoproline, thioproline andN-alkylalanine.

Preferably Z₁ is —NH₂.

Preferable Z₂ is —NH₂.

According to one aspect, preferred are compounds of formula (I) whereinXaa₁ is His or Tyr, more preferably His; Xaa₂ is Gly; Xaa₆ is Phe ornaphthylalanine; Xaa₁₄ is Leu, pentylglycine or Met; Xaa₂₂ is Phe ornaphthylalanine; Xaa₂₃ is Ile or Val; Xaa₃₁, Xaa₃₆, Xaa₃₇ and Xaa₃₈ areindependently selected from Pro, homoproline, thioproline orN-alkylalanine. More preferably Z, is —NH₂.

According to an especially preferred aspect, especially preferredcompounds include those of formula (I) wherein: Xaa₁ is His or Arg; Xaa₂is Gly or Ala; Xaa₃ is Asp or Glu; Xaa₅ is Ala or Thr; Xaa₆ is Ala, Pheor nephthylalaine; Xaa₇ is Thr or Ser; Xaa₈ is Ala, Ser or Thr; Xaa₉ isAsp or Glu; Xaa₁₀ is Ala, Leu or pentylglycine; Xaa₁₁ is Ala or Ser;Xaa₁₂ is Ala or Lys; Xaa₁₃ is Ala or Gln; Xaa₁₄ is Ala, Leu orpentylglycine; Xaa₁₅ is Ala or Glu; Xaa₁₆ is Ala or Glu; Xaa₁₇ is Ala orGlu; Xaa₁₉ is Ala or Val; Xaa₂₀ is Ala or Arg; Xaa₂₁ is Ala or Leu;Xaa₂₂ is Phe or naphthylalanine; Xaa₂₃ is Ile, Val or tert-butylglycine;Xaa₂₄ is Ala, Glu or Asp; Xaa₂₅ is Ala, Trp or Phe; Xaa₂₆ is Ala or Leu;Xaa₂₇ is Ala or Lys; Xaa₂₈ is Ala or Asn; Z₁ is —OH, —NH₂, Gly-Z₂, GlyGly-Z₂, Gly Gly Xaa₃₁-Z₂, Gly Gly Xaa₃₁ Ser-Z₂, Gly Gly Xaa₃₁ SerSer-Z₂, Gly Gly Xaa₃₁ Ser Ser Gly-Z₂, Gly Gly Xaa₃₁ Ser Ser Gly Ala-Z₂,Gly Gly Xaa₃₁ Ser Ser Gly Ala Xaa₃₆-Z₂, Gly Gly Xaa₃₁ Ser Ser Gly AlaXaa₃₆ Xaa₃₇-Z₂, Gly Gly Xaa₃₁ Ser Ser Gly Ala Xaa₃₆ Xaa₃₇ Xaa₃₈-Z₂;Xaa₃₁, Xaa₃₆, Xaa₃₇ and Xaa₃₈ being independently Pro homoproline,thioproline or N-methylalanine; and Z₂ being —OH or —NH₂; provided thatno more than three of Xaa₃, Xaa₅, Xaa₆, Xaa₈, Xaa₁₀, Xaa₁₁, Xaa₁₂,Xaa₁₃, Xaa₁₄, Xaa₁₅, Xaa₁₆, Xaa₁₇, Xaa₁₉, Xaa₂₀, Xaa₂₁, Xaa₂₄, Xaa₂₅,Xaa₂₆, Xaa₂₇ and Xaa₂₈ are Ala. Especially preferred compounds includethose having the amino acid sequence of SEQ. ID. NOS. 40-61.

According to an especially preferred aspect, provided are compoundswhere Xaa₁₄ is Leu, Ile, Val or pentylglycine, more preferably Leu orpentylglycine, and Xaa₂₅ is Phe, Tyr or naphthylalanine, more preferablyPhe or naphthylalanine. These compounds will be less susceptive tooxidative degration, both in vitro and in vivo, as well as duringsynthesis of the compound.

Exendin agonist compounds also include those described in U.S.Provisional Application No. 60/066,029, including compounds of theformula (III) [SEQ ID NO. 5]: Xaa₁ Xaa₂ Xaa₃ Xaa₄ Xaa₅ Xaa₆ Xaa₇ Xaa₈Xaa₉ Xaa₁₀ Xaa₁₁ Xaa₁₂ Xaa₁₃ Xaa₁₄ Xaa₁₅ Xaa₁₆ Xaa₁₇ Ala Xaa₁₉ Xaa₂₀Xaa₂₁ Xaa₂₂ Xaa₂₃ Xaa₂₄ Xaa₂₅ Xaa₂₆ Xaa₂₇ Xaa₂₈-Z₁;wherein

-   -   Xaa₁ is His, Arg, Tyr, Ala, Norval, Val or Norleu;    -   Xaa₂ is Ser, Gly, Ala or Thr;    -   Xaa₃ is Ala, Asp or Glu;    -   Xaa₄ is Ala, Norval, Val, Norleu or Gly;    -   Xaa₅ is Ala or Thr;    -   Xaa₆ is Phe, Tyr or naphthylalanine;    -   Xaa₇ is Thr or Ser;    -   Xaa₈ is Ala, Ser or Thr;    -   Xaa₉ is Ala, Norval, Val, Norleu, Asp or Glu;    -   Xaa₁₀ is Ala, Leu, Ile, Val, pentylglycine or Met;    -   Xaa₁₁ is Ala or Ser;    -   Xaa₁₂ is Ala or Lys;    -   Xaa₁₃ is Ala or Gln;    -   Xaa₁₄ is Ala, Leu, Ile, pentylglycine, Val or Met;    -   Xaa₁₅ is Ala or Glu;    -   Xaa₁₆ is Ala or Glu;    -   Xaa₁₇ is Ala or Glu;    -   Xaa₁₉ is Ala or Val;    -   Xaa₂₀ is Ala or Arg;    -   Xaa₂₁ is Ala or Leu;    -   Xaa₂₂ is Phe, Tyr or naphthylalanine;    -   Xaa₂₃ is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met;    -   Xaa₂₄ is Ala, Glu or Asp;    -   Xaa₂₅ is Ala, Trp, Phe, Tyr or naphthylalanine;    -   Xaa₂₆ is Ala or Leu;    -   Xaa₂₇ is Ala or Lys;    -   Xaa₂₈ is Ala or Asn;    -   Z₁ is —OH,        -   —NH₂,        -   Gly-Z₂,        -   Gly Gly-Z₂,        -   Gly Gly Xaa₃₁-Z₂,        -   Gly Gly Xaa₃₁ Ser-Z₂,        -   Gly Gly Xaa₃₁ Ser Ser-Z₂,        -   Gly Gly Xaa₃₁ Ser Ser Gly-Z₂,        -   Gly Gly Xaa₃₁ Ser Ser Gly Ala-Z₂,        -   Gly Gly Xaa₃₁ Ser Ser Gly Ala Xaa₃₆-Z₂,        -   Gly Gly Xaa₃₁ Ser Ser Gly Ala Xaa₃₆ Xaa₃₇-Z₂,        -   Gly Gly Xaa₃₁ Ser Ser Gly Ala Xaa₃₆ Xaa₃₇ Xaa₃₈-Z₂ or Gly            Gly Xaa₃₁ Ser Ser Gly Ala Xaa₃₆ Xaa₃₇ Xaa₃₈ Xaa₃₉-Z₂;            wherein        -   Xaa₃l, Xaa₃₆, Xaa₃₇ and Xaa₃₈ are independently Pro,            homoproline, 3Hyp, 4Hyp, thioproline,        -   N-alkylglycine, N-alkylpentylglycine or        -   N-alkylalanine; and        -   Z₂ is —OH or —NH₂;            provided that no more than three of Xaa₃, Xaa₄, Xaa₅, Xaa₆,            Xaa8, Xaa₉, Xaa₁₀, Xaa₁₁, Xaa₁₂, Xaa₁₃, Xaa₁₄, Xaa₁₅, Xaa₁₆,            Xaa₁₇, Xaa₁₉, Xaa₂₀, Xaa₂₁, Xaa₂₄, Xaa₂₅, Xaa₂₆, Xaa₂₇ and            Xaa₂₈ are Ala; and provided also that, if Xaa₁ is His, Arg            or Tyr, then at least one of Xaa₃, Xaa₄ and Xaa₉ is Ala.            Definitions

In accordance with the present invention and as used herein, thefollowing terms are defined to have the following meanings, unlessexplicitly stated otherwise.

The term “amino acid” refers to natural amino acids, unnatural aminoacids, and amino acid analogs, all in their D and L stereoisomers iftheir structure allow such stereoisomeric forms. Natural amino acidsinclude alanine (Ala), arginine (Arg), asparagine (Asn), aspartic acid(Asp), cysteine (Cys), glutamine (Gln), glutamic acid (Glu), glycine(Gly), histidine (His), isoleucine (Ile), leucine (Leu), Lysine (Lys),methionine (Met), phenylalanine (Phe), proline (Pro), serine (Ser),threonine (Thr), typtophan (Trp), tyrosine (Tyr) and valine (Val).Unnatural amino acids include, but are not limited toazetidinecarboxylic acid, 2-aminoadipic acid, 3-aminoadipic acid,beta-alanine, aminopropionic acid, 2-aminobutyric acid, 4-aminobutyricacid, 6-aminocaproic acid, 2-aminoheptanoic acid, 2-aminoisobutyricacid, 3-aminoisbutyric acid, 2-aminopimelic acid, tertiary-butylglycine,2,4-diaminoisobutyric acid, desmosine, 2,2′-diaminopimelic acid,2,3-diaminopropionic acid, N-ethylglycine, N-ethylasparagine,homoproline, hydroxylysine, allo-hydroxylysine, 3-hydroxyproline,4-hydroxyproline, isodesmosine, allo-isoleucine, N-methylalanine,N-methylglycine, N-methylisoleucine, N-methylpentylglycine,N-methylvaline, naphthalanine, norvaline, norleucine, ornithine,pentylglycine, pipecolic acid and thioproline. Amino acid analogsinclude the natural and unnatural amino acids which are chemicallyblocked, reversibly or irreversibly, or modified on their N-terminalamino group or their side-chain groups, as for example, methioninesulfoxide, methionine sulfone, S-(carboxymethyl)-cysteine,S-(carboxymethyl)-cysteine sulfoxide and S-(carboxymethyl)-cysteinesulfone.

The term “amino acid analog” refers to an amino acid wherein either theC-terminal carboxy group, the N-terminal amino group or side-chainfunctional group has been chemically codified to another functionalgroup. For example, aspartic acid-(beta-methyl ester) is an amino acidanalog of aspartic acid; N-ethylglycine is an amino acid analog ofglycine; or alanine carboxamide is an amino acid analog of alanine.

The term “amino acid residue” refers to radicals having the structure:(1) —C(O)—R—NH—, wherein R typically is —CH(R′)—, wherein R′ is an aminoacid side chain, typically H or a carbon containing substitutent; or(2),

wherein p is 1, 2 or 3 representing the azetidinecarboxylic acid,proline or pipecolic acid residues, respectively.

The term “lower” referred to herein in connection with organic radicalssuch as alkyl groups defines such groups with up to and including about6, preferably up to and including 4 and advantageously one or two carbonatoms. Such groups may be straight chain or branched chain.

“Pharmaceutically acceptable salt” includes salts of the compoundsdescribed herein derived from the combination of such compounds and anorganic or inorganic acid. In practice the use of the salt form amountsto use of the base form. The compounds are useful in both free base andsalt form.

In addition, the following abbreviations stand for the following:

-   -   “ACN” or “CH₃CN” refers to acetonitrile.    -   “Boc”, “tBoc” or “Tboc” refers to t-butoxy carbonyl.    -   “DCC” refers to N,N′-dicyclohexylcarbodiimide.    -   “Fmoc” refers to fluorenylmethoxycarbonyl.    -   “HBTU” refers to        2-(1H-benzotriazol-1-yl)-1,1,3,3,-tetramethyluronium        hexaflurophosphate.    -   “HOBt” refers to 1-hydroxybenzotriazole monohydrate.    -   “homop” or hpro” refers to homoproline.    -   “MeAla” or “Nme” refers to N-methylalanine.    -   “naph” refers to naphthylalanine.    -   “pG” or pGly” refers to pentylglycine.    -   “tBuG” refers to tertiary-butylglycine.    -   “ThioP” or tPro” refers to thioproline.    -   3Hyp” refers to 3-hydroxyproline    -   4Hyp” refers to 4-hydroxyproline    -   NAG” refers to N-alkylglycine    -   NAPG” refers to N-alkylpentylglycine    -   “Norval” refers to norvaline    -   “Norleu” refers to norleucine        Preparation of Compounds

The exendins and exendin agonists described herein may be prepared usingstandard solid-phase peptide synthesis techniques and preferably anautomated or semiautomated peptide synthesizer. Typically, using suchtechniques, an α-N-carbamoyl protected amino acid and an amino acidattached to the growing peptide chain on a resin are coupled at roomtemperature in an inert solvent such as dimethylformamide,N-methylpyrrolidinone or methylene chloride in the presence of couplingagents such as dicyclohexylcarbodiimide and 1-hydroxybenzotriazole inthe presence of a base such as diisopropylethylamine. The α-N-carbamoylprotecting group is removed from the resulting peptide-resin using areagent such as trifluoroacetic acid or piperidine, and the couplingreaction repeated with the next desired N-protected amino acid to beadded to the peptide chain. Suitable N-protecting groups are well knownin the art, with t-butyloxycarbonyl (tBoc) and fluorenylmethoxycarbonyl(Fmoc) being preferred herein.

The solvents, amino acid derivatives and 4-methylbenzhydryl-amine resinused in the peptide synthesizer may be purchased from Applied BiosystemsInc. (Foster City, Calif.). The following side-chain protected aminoacids may be purchased from Applied Biosystems, Inc.: Boc-Arg(Mts),Fmoc-Arg(Pmc), Boc-Thr(Bzl), Fmoc-Thr(t-Bu), Boc-Ser(Bzl),Fmoc-Ser(t-Bu), Boc-Tyr(BrZ), Fmoc-Tyr(t-Bu), Boc-Lys(Cl-Z),Fmoc-Lys(Boc), Boc-Glu(Bzl), Fmoc-Glu(t-Bu), Fmoc-His(Trt),Fmoc-Asn(Trt), and Fmoc-Gln(Trt). Boc-His(BOM) may be purchased fromApplied Biosystems, Inc. or Bachem Inc. (Torrance, Calif.). Anisole,dimethylsulfide, phenol, ethanedithiol, and thioanisole may be obtainedfrom Aldrich Chemical Company (Milwaukee, Wis.). Air Products andChemicals (Allentown, Pa.) supplies HF. Ethyl ether, acetic acid andmethanol may be purchased from Fisher Scientific (Pittsburgh, Pa.).

Solid phase peptide synthesis may be carried out with an automaticpeptide synthesizer (Model 430A, Applied Biosystems Inc., Foster City,Calif.) using the NMP/HOBt (Option 1) system and tBoc or Fmoc chemistry(see, Applied Biosystems User's Manual for the ABI 430A PeptideSynthesizer, Version 1.3B Jul. 1, 1988, section 6, pp. 49-70, AppliedBiosystems, Inc., Foster City, Calif.) with capping. Boc-peptide-resinsmay be cleaved with HF (−5° C. to 0° C., 1 hour). The peptide may beextracted from the resin with alternating water and acetic acid, and thefiltrates lyophilized. The Fmoc-peptide resins may be cleaved accordingto standard methods (Introduction to Cleavage Techniques, AppliedBiosystems, Inc., 1990, pp. 6-12). Peptides may be also be assembledusing an Advanced Chem Tech Synthesizer (Model MPS 350,. Louisville,Ky.).

Peptides may be purified by RP-HPLC (preparative and analytical) using aWaters Delta Prep 3000 system. A C4, C8 or C18 preparative column (10μ,2.2×25 cm; Vydac, Hesperia, Calif.) may be used to isolate peptides, andpurity may be determined using a C4, C8 or C18 analytical column (5μ,0.46×25 cm; Vydac). Solvents (A=0.1% TFA/water and B=0.1% TFA/CH₃CN) maybe delivered to the analytical column at a flowrate of 1.0 ml/min and tothe preparative column at 15 ml/min. Amino acid analyses may beperformed on the Waters Pico Tag system and processed using the Maximaprogram. Peptides may be hydrolyzed by vapor-phase acid hydrolysis (115°C., 20-24 h). Hydrolysates may be derivatized and analyzed by standardmethods (Cohen, et al., The Pico Tag Method: A Manual of AdvancedTechniques for Amino Acid Analysis, pp. 11-52, Millipore Corporation,Milford, Mass. (1989)). Fast atom bombardment analysis may be carriedout by M-Scan, Incorporated (West Chester, Pa.). Mass calibration may beperformed using cesium iodide or cesium iodide/glycerol. Plasmadesorption ionization analysis using time of flight detection may becarried out on an Applied Biosystems Bio-Ion 20 mass spectrometer.Electrospray mass spectroscopy may be carried out on a VG-Trio machine.

Peptide compounds useful in the invention may also be prepared usingrecombinant DNA techniques, using methods now known in the art. See,e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2d Ed.,Cold Spring Harbor (1989). Non-peptide compounds useful in the presentinvention may be prepared by art-known methods. For example,phosphate-containing amino acids and peptides containing such aminoacids, may be prepared using methods known in the art. See. e.g.,Bartlett and Landen, Biorg. Chem. 14:356-377 (1986).

The compounds described above are useful in view of theirpharmacological properties. In particular, the compounds of theinvention possess activity as agents to reduce food intake. They can beused to treat conditions or diseases which can be alleviated by reducingfood intake.

Compositions useful in the invention may conveniently be provided in theform of formulations suitable for parenteral (including intravenous,intramuscular and subcutaneous) or nasal or oral administration. In somecases, it will be convenient to provide an exendin or exendin agonistand another food-intake-reducing, plasma glucose-lowering or plasmalipid-lowering agent, such as amylin, an amylin agonist, a CCK, or aleptin, in a single composition or solution for administration together.In other cases, it may be more advantageous to administer the additionalagent separately from said exendin or exendin agonist. A suitableadministration format may best be determined by a medical practitionerfor each patient individually. Suitable pharmaceutically acceptablecarriers and their formulation are described in standard formulationtreatises, e.g., Remington's Pharmaceutical Sciences by E. W. Martin.See also Wang, Y. J. and Hanson, M. A. “Parenteral Formulations ofProteins and Peptides: Stability and Stabilizers,” Journal of ParenteralScience and Technology, Technical Report No. 10, Supp. 42:2S (1988).

Compounds useful in the invention can be provided as parenteralcompositions for injection or infusion. They can, for example, besuspended in an inert oil, suitably a vegetable oil such as sesame,peanut, olive oil, or other acceptable carrier. Preferably, they aresuspended in an aqueous carrier, for example, in an isotonic buffersolution at a pH of about 3.0 to 8.0, preferably at a pH of about 3.5 to5.0. These compositions may be sterilized by conventional sterilizationtechniques, or may be sterile filtered. The compositions may containpharmaceutically acceptable auxiliary substances as required toapproximate physiological conditions, such as pH buffering agents.Useful buffers include for example, sodium acetate/acetic acid buffers.A form of repository or “depot” slow release preparation may be used sothat therapeutically effective amounts of the preparation are deliveredinto the bloodstream over many hours or days following transdermalinjection or delivery.

The desired isotonicity may be accomplished using sodium chloride orother pharmaceutically acceptable agents such as dextrose, boric acid,sodium tartrate, propylene glycol, polyols (such as mannitol andsorbitol), or other inorganic or organic solutes. Sodium chloride ispreferred particularly for buffers containing sodium ions.

The claimed compositions can also be formulated as pharmaceuticallyacceptable salts (e.g., acid addition salts) and/or complexes thereof.Pharmaceutically acceptable salts are non-toxic salts at theconcentration at which they are administered. The preparation of suchsalts can facilitate the pharmacological use by altering thephysical-chemical characteristics of the composition without preventingthe composition from exerting its physiological effect. Examples ofuseful alterations in physical properties include lowering the meltingpoint to facilitate transmucosal administration and increasing thesolubility to facilitate the administration of higher concentrations ofthe drug.

Pharmaceutically acceptable salts include acid addition salts such asthose containing sulfate, hydrochloride, phosphate, sulfamate, acetate,citrate, lactate, tartrate, methanesulfonate, ethanesulfonate,benzenesulfonate, p-toluenesulfonate, cyclohexylsulfamate and quinate.Pharmaceutically acceptable salts can be obtained from acids such ashydrochloric acid, sulfuric acid, phosphoric acid, sulfamic acid, aceticacid, citric acid, lactic acid, tartaric acid, malonic acid,methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid,p-toluenesulfonic acid, cyclohexylsulfamic acid, and quinic acid. Suchsalts may be prepared by, for example, reacting the free acid or baseforms of the product with one or more equivalents of the appropriatebase or acid in a solvent or medium in which the salt is insoluble, orin a solvent such as water which is then removed in vacuo or byfreeze-drying or by exchanging the ions of an existing salt for anotherion on a suitable ion exchange resin.

Carriers or excipients can also be used to facilitate administration ofthe compound. Examples of carriers and excipients include calciumcarbonate, calcium phosphate, various sugars such as lactose, glucose,or sucrose, or types of starch, cellulose derivatives, gelatin,vegetable oils, polyethylene glycols and physiologically compatiblesolvents. The compositions or pharmaceutical composition can beadministered by different routes including intravenously,intraperitoneal, subcutaneous, and intramuscular, orally, topically,transmucosally, or by pulmonary inhalation.

If desired, solutions of the above compositions may be thickened with athickening agent such as methyl cellulose. They may be prepared inemulsified form, either water in oil or oil in water. Any of a widevariety of pharmaceutically acceptable emulsifying agents may beemployed including, for example, acacia powder, a non-ionic surfactant(such as a Tween), or an ionic surfactant (such as alkali polyetheralcohol sulfates or sulfonates, e.g., a Triton) Compositions useful inthe invention are prepared by mixing the ingredients following generallyaccepted procedures. For example, the selected components may be simplymixed in a blender or other standard device to produce a concentratedmixture which may then be adjusted to the final concentration andviscosity by the addition of water or thickening agent and possibly abuffer to control pH or an additional solute to control tonicity.

For use by the physician, the compositions will be provided in dosageunit form containing an amount of an exendin or exendin agonist, forexample, exendin-3, and/or exendin-4, with or without another foodintake-reducing, plasma glucose-lowering or plasma lipid-lowering agent.Therapeutically effective amounts of an exendin or exendin agonist foruse in reducing food intake are those that suppress appetite at adesired level. As will be recognized by those in the field, an effectiveamount of therapeutic agent will vary with many factors including theage and weight of the patient, the patient's physical condition, theblood sugar level and other factors.

The effective daily appetite-suppressing dose of the compounds willtypically be in the range of about 10 to 30 μg to about 5 mg/day,preferably about 10 to 30 μg to about 2 mg/day and more preferably about10 to 100 μg to about 1 mg/day, most preferably about 30 μg to about 500μg/day, for a 70 kg patient, administered in a single or divided doses.The exact dose to be administered is determined by the attendingclinician and is dependent upon where the particular compound lieswithin the above quoted range, as well as upon the age, weight andcondition of the individual. Administration should begin whenever thesuppression of food intake, or weight lowering is desired, for example,at the first sign of symptoms or shortly after diagnosis of obesity,diabetes mellitus, or insulin-resistance syndrome. Administration may beby injection, preferably subcutaneous or intramuscular orally activecompounds may be taken orally, however dosages should be increased 5-10fold.

The optimal formulation and mode of administration of compounds of thepresent application to a patient depend on factors known in the art suchas the particular disease or disorder, the desired effect, and the typeof patient. While the compounds will typically be used to treat humansubjects they may also be used to treat similar or identical diseases inother vertebrates such as other primates, farm animals such as swine,cattle and poultry, and sports animals and pets such as horses, dogs andcats.

To assist in understanding the present invention, the following Examplesare included. The experiments relating to this invention should not, ofcourse, be construed as specifically limiting the invention and suchvariations of the invention, now known or later developed, which wouldbe within the purview of one skilled in the art are considered to fallwithin the scope of the invention as described herein and hereinafterclaimed.

EXAMPLE 1 Exendin Injections Reduced the Food Intake of Normal Mice

All mice (NIH:Swiss mice) were housed in a stable environment of 22(±2)° C., 60 (±10) % humidity and a 12:12 light:dark cycle; with lightson at 0600. Mice were housed in groups of four in standard cages with adlibitum access to food (Teklad: LM 485; Madison, Wis.) and water exceptas noted, for at least two weeks before the experiments.

All experiments were conducted between the hours of 0700 and.0900. Themice were food deprived (food removed at 1600 hr from all animals on dayprior to experiment) and individually housed. All mice received anintraperitoneal injection (5 μl/kg) of either saline or exendin-4 atdoses of 0.1, 1.0, 10 and 100 μg/kg and were immediately presented witha pre-weighed food pellet (Teklad LM 485). The food pellet was weighedat 30-minute, 1-hr, 2-hr and 6-hr intervals to determine the amount offood eaten.

FIG. 1 depicts cumulative food intake over periods of 0.5, 1, 2 and 6 hrin overnight-fasted normal NIH:Swiss mice following ip injection ofsaline, 2 doses of GLP-1, or 4 doses of exendin-4. At doses up to 100μg/kg, GLP-1 had no effect on food intake measured over any period, aresult consistent with that previously reported (Bhavsar, S. P., et al.,Soc. Neurosci. Abstr. 21:460 (188.8) (1995); and Turton, M. D., Nature,379:69-72, (1996)).

In contrast, exendin-4 injections potently and dose-dependentlyinhibited food intake. The ED₅₀ for inhibition of food intake over 30min was 1 μg/kg, which is a level about as potent as amylin (ED₅₀ 3.6μg/kg) or the prototypical peripheral satiety agent, CCK (ED₅₀ 0.97μg/kg) as measured in this preparation. However, in contrast to theeffects of amylin or CCK, which abate after 1-2 hours, the inhibition offood intake with exendin-4 was still present after at least 6 hoursafter injection.

EXAMPLE 2 Exendin Reduced the Food Intake of Obese Mice

All mice (female ob/ob mice) were housed in a stable environment of 22(±2)° C., 60 (±10) % humidity and a 12:12 light:dark cycle; with lightson at 0600. Mice were housed in groups of four in standard cages with adlibitum access to food (Teklad: LM 485) and water except as noted, forat least two weeks before the experiments.

All experiments were conducted between the hours of 0700 and 0900. Themice were food deprived (food removed at 1600 hr from all animals on dayprior to experiment) and individually housed. All mice received anintraperitoneal injection (5 μl/kg) of either saline or exendin-4 atdoses of 0.1, 1.0 and 10 μg/kg (female ob/ob mice) and were immediatelypresented with a pre-weighed food pellet (Teklad LM 485). The foodpellet was weighed at 30-minute, 1 -hr, 2-hr and 6-hr intervals todetermine the amount of food eaten.

FIG. 2 depicts the effect of exendin-4 in the ob/ob mouse model ofobesity. The obese mice had a similar food intake-related response toexendin as the normal mice. Moreover, the obese mice were nothypersensitive to exendin, as has been observed with amylin and leptin(Young, A. A., et al., Program and Abstracts, 10th InternationalCongress of Endocrinology, Jun. 12-15, 1996 San Francisco, pg 419(P2-58)).

EXAMPLE 3 Intracerebroventricular Injections of Exendin Inhibited FoodIntake in Rats

All rats (Harlan Sprague-Dawley) were housed in a stable environment of22 (±2)° C., 60 (±10) % humidity and a 12:12 light:dark cycle; withlights on at 0600. Rats were obtained from Zivic Miller with anintracerebroventricular cannula (ICV cannula) implanted (coordinatesdetermined by actual weight of animals and referenced to Paxinos, G. andWatson, C. “The Rat Brain in stereotaxic coordinates,” second edition.Academic Press) and were individually housed in standard cages with adlibitum access to food (Teklad: LM 485) and water for at least one weekbefore the experiments.

All injections were given between the hours of 1700 and 1800. The ratswere habituated to the ICV injection procedure at least once before theICV administration of compound. All rats received an ICV injection (2μl/30 seconds) of either saline or exendin-4 at doses of 0.01, 0.03,0.1, 0.3, and 1.0 μg. All animals were then presented with pre-weighedfood (Teklad LM 485) at 1800, when the lights were turned off. Theamount of food left was weighed at 2-hr, 12-hr and 24-hr intervals todetermine the amount of food eaten by each animal.

FIG. 3 depicts a dose-dependent inhibition of food intake in rats thatreceived doses greater than 0.1 μg/rat. The ED₅₀ was≈0.1 μg, exendin-4is thus≈100-fold more potent than intracerebroventricular injections ofGLP-1 as reported by Turton, M. D., et al. (Nature 379:69-72 (1996)).

EXAMPLE 4 Exendin Agonists Reduced the Food Intake in Mice

All mice (NIH:Swiss mice) were housed in a stable environment of 22(±2)° C., 60 (±10) % humidity and a 12:12 light:dark cycle; with lightson at 0600. Mice were housed in groups of four in standard cages with adlibitum access to food (Teklad: LM 485; Madison, Wis.) and water exceptas noted, for at least two weeks before the experiments.

All experiments were conducted between the hours of 0700 and 0900. Themice were food deprived (food removed at 1600 hr from all animals on dayprior to experiment) and individually housed. All mice received anintraperitoneal injection (5 μl/kg) of either saline or test compound atdoses of 1, 10, and 100 μg/kg and immediately presented with a foodpellet (Teklad LM 485). The food pellet was weighed at 30-minute, 1-hr,2-hr and 6-hr intervals to determine the amount of food eaten.

FIG. 4 depicts the cumulative food intake over periods of 0.5, 1, 2 and6 hr in overnight-fasted normal NIH:Swiss mice following ip injection-ofsaline or exendin-4 (1-30) (“Compound 1”) in doses of 1, 10 and 100μg/kg.

FIG. 5 depicts the cumulative food intake over periods of 0.5, 1, 2 and6 hr in overnight-fasted normal NIH:Swiss mice following ip injection ofsaline or exendin-4 (1-30) amide (“Compound 2”) in doses of 1, 10 and100 μg/kg.

FIG. 6 depicts the cumulative food intake over periods of 0.5, 1, 2 and6 hr in overnight-fasted normal NIH:Swiss mice following ip injection ofsaline or exendin-4 (1-28) amide (“Compound 3”) in doses of 1, 10 and100 μg/kg.

FIG. 7 depicts the cumulative food intake over periods of 0.5, 1, 2 and6 hr in overnight-fasted normal NIH:Swiss mice following ip injection ofsaline or ¹⁴Leu, ²⁵Phe exendin-4 amide (“Compound 4”) in doses of 1, 10and 100 μg/kg.

FIG. 8 depicts the cumulative food intake over periods of 0.5, 1, 2 and6 hr in overnight-fasted normal NIH:Swiss mice following ip injection ofsaline or ¹⁴Leu,²⁵Phe exendin-4 (1-28) amide (“Compound 5”) in doses of1, 10 and 100 μg/kg.

FIG. 9 depicts the cumulative food intake over periods of 0.5, 1, 2 and6 hr in overnight-fasted normal NIH:Swiss mice following ip injection ofsaline or ¹⁴Leu,²²Ala,²⁵Phe exendin-4 (1-28) amide (“Compound 6”) indoses of 1, 10 and 100 μg/kg.

EXAMPLE 5 Preparation of Amidated Peptide Having SEQ. ID. NO. 9

The above-identified peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.). In general, single-coupling cycles were usedthroughout the synthesis and Fast Moc (HBTU activation) chemistry wasemployed. However, at some positions coupling was less efficient thanexpected and double couplings were required. In particular, residuesAsp₉, Thr₇ and Phe₆ all required double coupling. Deprotection (Fmocgroup removal)of the growing peptide chain using piperidine was notalways efficient. Double deprotection was required at positions Arg₂₀,Val₁₉ and Leu₁₄. Final deprotection of the completed peptide resin wasachieved using a mixture of triethylsilane (0.2 mL), ethanedithiol (0.2mL), anisole (0.2 mL), water (0.2 mL) and trifluoroacetic acid (15 mL)according to standard methods (Introduction to Cleavage Techniques,Applied Biosystems, Inc.) The peptide was precipitated in ether/water(50 mL) and centrifuged. The precipitate was reconstituted in glacialacetic acid and lyophilized. The lyophilized peptide was dissolved inwater). Crude purity was about 55%.

Used in purification steps and analysis were Solvent A (0.1% TFA inwater) and Solvent B (0.1% TFA in ACN).

The solution containing peptide was applied to a preparative C-18 columnand purified (10% to 40% Solvent B in Solvent A over 40 minutes). Purityof fractions was determined isocratically using a C-18 analyticalcolumn. Pure fractions were pooled furnishing the above-identifiedpeptide. Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent Aover 30 minutes) of the lyophilized peptide gave product peptide havingan observed retention time of 14.5 minutes. Electrospray MassSpectrometry (M): calculated 4131.7; found 4129.3.

EXAMPLE 6 Preparation of Peptide Having SEQ. ID. NO. 10

The above-identified peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Used in analysis were Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 25% to 75% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide gave product peptide having an observed retentiontime of 21.5 minutes. Electrospray Mass Spectrometry (M): calculated4168.6; found 4171.2.

EXAMPLE 7 Preparation of Peptide Having SEQ. ID. NO. 11

The above-identified peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Used in analysis were Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide gave product peptide having an observed retentiontime of 17.9 minutes. Electrospray Mass Spectrometry (M): calculated4147.6; found 4150.2.

EXAMPLE 8 Preparation of Peptide having SEQ. ID. NO. 12

The above-identified peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Used in analysis were Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 35% to 65% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide gave product peptide having an observed retentiontime of 19.7 minutes. Electrospray Mass Spectrometry (M): calculated4212.6; found 4213.2.

EXAMPLE 9 Preparation of Peptide Having SEQ. ID. NO. 13

The above-identified peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Used in analysis were Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 50% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide gave product peptide having an observed retentiontime of 16.3 minutes. Electrospray Mass Spectrometry (M): calculated4262.7; found 4262.4.

EXAMPLE 10 Preparation of Peptide Having SEQ. ID. NO. 14

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated4172.6

EXAMPLE 11 Preparation of Peptide having SEQ. ID. NO. 15

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl-phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated4224.7.

EXAMPLE 12 Preparation of Peptide Having SEQ. ID. NO. 16

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated4172.6

EXAMPLE 13 Preparation of Peptide Having SEQ. ID. NO. 17

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated4186.6

EXAMPLE 14 Preparation of Peptide Having SEQ. ID. NO. 18

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated4200.7

EXAMPLE 15 Preparation of Peptide Having SEQ. ID. NO. 19

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated4200.7

EXAMPLE 16 Preparation of Peptide Having SEQ. ID. NO. 20

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated4202.7.

EXAMPLE 17 Preparation of Peptide Having SEQ. ID. NO. 21

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated4145.6.

EXAMPLE 18 Preparation of Peptide Having SEQ. ID. NO. 22

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated4184.6.

EXAMPLE 19 Preparation of Peptide Having SEQ. ID. NO. 23

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated4145.6.

EXAMPLE 20 Preparation of Peptide Having SEQ. ID. NO. 24

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated4224.7.

EXAMPLE 21 Preparation of Peptide Having SEQ. ID. NO. 25

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated4172.6.

EXAMPLE 22 Preparation of Peptide Having SEQ. ID. NO. 26

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated4115.5.

EXAMPLE 23 Preparation of Peptide Having SEQ. ID. NO. 27

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated4188.6.

EXAMPLE 24 Preparation of Peptide Having SEQ. ID. NO. 28

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated4131.6.

EXAMPLE 25 Preparation of Peptide Having SEQ. ID. NO. 29

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated4172.6.

EXAMPLE 26 Preparation of Peptide Having SEQ. ID. NO. 30

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated4145.6.

EXAMPLE 27 Preparation of Peptide Having SEQ. ID. NO. 31

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Additional double couplings arerequired at the thioproline positions 38, 37, 36 and 31. Used inanalysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA inACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent Aover 30 minutes) of the lyophilized peptide is then carried out todetermine the retention time of the product peptide. Electrospray MassSpectrometry (M): calculated 4266.8.

EXAMPLE 28 Preparation of Peptide having SEQ. ID. NO. 32

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Additional double couplings arerequired at the thioproline positions 38, 37 and 36. Used in analysisare Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30minutes) of the lyophilized peptide is then carried out to determine theretention time of the product peptide. Electrospray Mass Spectrometry(M): calculated 4246.8.

EXAMPLE 29 Preparation of Peptide Having SEQ. ID. NO. 33

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Additional double couplings arerequired at the homoproline positions 38, 37, 36 and 31. Used inanalysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA inACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent Aover 30 minutes) of the lyophilized peptide is then carried out todetermine the retention time of the product peptide. Electrospray MassSpectrometry (M): calculated 4250.8.

EXAMPLE 30 Preparation of Peptide Having SEQ. ID. NO. 34

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Additional double couplings arerequired at the homoproline positions 38, 37, and 36. Used in analysisare Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN).Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30minutes) of the lyophilized peptide is then carried out to determine theretention time of the product peptide. Electrospray Mass Spectrometry(M): calculated 4234.8.

EXAMPLE 31 Preparation of Peptide having SEQ. ID. NO. 35

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Additional double couplings arerequired at the thioproline positions 38, 37, 36 and 31. Used inanalysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA inACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent Aover 30 minutes) of the lyophilized peptide is then carried out todetermine the retention time of the product peptide. Electrospray MassSpectrometry (M): calculated 4209.8.

EXAMPLE 32 Preparation of Peptide Having SEQ. ID. NO. 36

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Additional double couplings arerequired at the homoproline positions 38, 37, 36 and 31. Used inanalysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA inACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent Aover 30 minutes) of the lyophilized peptide is then carried out todetermine the retention time of the product peptide. Electrospray MassSpectrometry (M): calculated 4193.7.

EXAMPLE 33 Preparation of Peptide Having SEQ. ID. NO. 37

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Additional double couplings arerequired at the N-methylalanine positions 38, 37, 36 and 31. Used inanalysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA inACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent Aover 30 minutes) of the lyophilized peptide is then carried out todetermine the retention time of the product peptide. Electrospray MassSpectrometry (M): calculated 3858.2.

EXAMPLE 34 Preparation of Peptide Having SEQ. ID. NO. 38

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Additional double couplings arerequired at the N-methylalanine positions 38, 37 and 36. Used inanalysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA inACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent Aover 30 minutes) of the lyophilized peptide is then carried out todetermine the retention time of the product peptide. Electrospray MassSpectrometry (M): calculated 3940.3.

EXAMPLE 35 Preparation of Peptide Having SEQ. ID. NO. 39

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 5. Additional double couplings arerequired at the N-methylalanine positions 38, 37, 36 and 31. Used inanalysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA inACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent Aover 30 minutes) of the lyophilized peptide is then carried out todetermine the retention time of the product peptide. Electrospray MassSpectrometry (M): calculated 3801.1.

EXAMPLE 36 Preparation of C-Terminal Carboxylic Acid PeptidesCorresponding to the above C-Terminal Amide Sequences

The above peptides of Examples 5 to 35 are assembled on the so calledWang resin (p-alkoxybenzylalacohol resin (Bachem, 0.54 mmole/g)) usingFmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from theresin, deprotected and purified in a similar way to Example 5. Used inanalysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA inACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent Aover 30 minutes) of the lyophilized peptide is then carried out todetermine the retention time of the product peptide. Electrospray MassSpectrometry provides an experimentally determined (M).

EXAMPLE 37 Preparation of Peptide Having SEQ. ID. NO. 7

His Gly Glu Gly Thr Phe Thr Ser Asp [SEQ. ID. NO. 7] Leu Ser Lys Gln MetGlu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly-NH₂

The above amidated peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.). In general, single-coupling cycles were usedthroughout the synthesis and Fast Moc (HBTU activation) chemistry wasemployed. Deprotection (Fmoc group removal)of the growing peptide chainwas achieved using piperidine. Final deprotection of the completedpeptide resin was achieved using a mixture of triethylsilane (0.2 mL),ethanedithiol (0.2 mL), anisole (0.2 mL), water (0.2 mL) andtrifluoroacetic acid (15 mL) according to standard methods (Introductionto Cleavage Techniques, Applied Biosystems, Inc.) The peptide wasprecipitated in ether/water (50 mL) and centrifuged. The precipitate wasreconstituted in glacial acetic acid and lyophilized. The lyophilizedpeptide was dissolved in water). Crude purity was about 75%.

Used in purification steps and analysis were Solvent A (0.1% TFA inwater) and Solvent B (0.1% TFA in ACN). The solution containing peptidewas applied to a preparative C-18 column and purified (10% to 40%Solvent B in Solvent A over 40 minutes). Purity of fractions wasdetermined isocratically using a C-18 analytical column. Pure fractionswere pooled furnishing the above-identified peptide. Analytical RP-HPLC(gradient 30% to 50% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide gave product peptide having an observed retentiontime of 18.9 minutes. Electrospray Mass Spectrometry (M): calculated3408.0; found 3408.9.

EXAMPLE 38

Preparation of Peptide Having SEQ ID NO. 40 His Gly Glu Gly Thr Phe ThrSer [SEQ. ID. NO. 40] Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val ArgLeu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above amidated peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis were Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 40% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide gave product peptide having an observed retentiontime of 17.9 minutes. Electrospray Mass Spectrometry (M): calculated3294.7; found 3294.8.

EXAMPLE 39 Preparation of Peptide having SEQ ID NO. 41

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 41] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis were Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 29% to 36% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide gave product peptide having an observed retentiontime of 20.7 minutes. Electrospray Mass Spectrometry (M): calculated3237.6; found 3240.

EXAMPLE 40 Preparation of Peptide Having SEQ ID NO. 42

His Ala Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 42] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above amidated peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis were Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 36% to 46% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide gave product peptide having an observed retentiontime of 15.2 minutes. Electrospray Mass Spectrometry (M): calculated3251.6; found 3251.5.

EXAMPLE 41 Preparation of Peptide having SEQ ID NO. 43

    His Gly Glu Gly Ala Phe Thr [SEQ. ID. NO. 43] Ser Asp Leu Ser LysGln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above amidated peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis were Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 36% to 46% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide gave product peptide having an observed retentiontime of 13.1 minutes. Electrospray Mass Spectrometry (M): calculated3207.6; found 3208.3.

EXAMPLE 42 Preparation of Peptide Having SEQ ID NO. 44

His Gly Glu Gly Thr Ala Thr Ser [SEQ. ID. NO. 44] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above amidated peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis were Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 35% to 45% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide gave product peptide having an observed retentiontime of 12.8 minutes. Electrospray Mass Spectrometry (M): calculated3161.5; found 3163.

EXAMPLE 43 Preparation of Peptide having SEQ ID NO. 45

His Gly Glu Gly Thr Phe Thr Ala [SEQ. ID. NO. 45] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis were Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 36% to 46% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide gave product peptide having an observed retentiontime of 15.2 minutes. Electrospray Mass Spectrometry (M): calculated3221.6; found 3222.7.

EXAMPLE 44 Preparation of Peptide Having SEQ ID NO. 46

[SEQ. ID. NO. 46] His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis were Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 34% to 44% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide gave product peptide having an observed retentiontime of 14.3 minutes. Electrospray Mass Spectrometry (M): calculated3195.5; found 3199.4.

EXAMPLE 45 Preparation of Peptide Having SEQ ID NO. 47

[SEQ. ID. NO. 47] His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ala Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis were Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 38% to 48% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide gave product peptide having an observed retentiontime of 15.7 minutes. Electrospray Mass Spectrometry (M): calculated3221.6; found 3221.6.

EXAMPLE 46 Preparation of Peptide having SEQ ID NO. 48

[SEQ. ID. NO. 48] His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Ala GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis were Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 38% to 48% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide gave product peptide having an observed retentiontime of 18.1 minutes. Electrospray Mass Spectrometry (M): calculated3180.5; found 3180.9.

EXAMPLE 47 Preparation of Peptide Having SEQ ID NO. 49

[SEQ. ID. NO. 49] His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys AlaLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Compound 1. Used in analysis were Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 36% to 46% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide gave product peptide having an observed retentiontime of 17.0 minutes. Electrospray Mass Spectrometry (M): calculated3180.6; found 3182.8.

EXAMPLE 48 Preparation of Peptide Having SEQ ID NO. 50

[SEQ. ID. NO. 50] His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys GlnAla Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis were Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 32% to 42% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide gave product peptide having an observed retentiontime of 14.9 minutes. Electrospray Mass Spectrometry (M): calculated3195.5; found 3195.9.

EXAMPLE 49 Preparation of Peptide Having SEQ ID NO. 51

[SEQ. ID. NO. 51] His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys GlnLeu Ala Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis were Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 37% to 47% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide gave product peptide having an observed retentiontime of 17.9 minutes. Electrospray Mass Spectrometry (M): calculated3179.6; found 3179.0.

EXAMPLE 50 Preparation of Peptide having SEQ ID NO. 52

[SEQ. ID. NO. 52] His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys GlnLeu Glu Ala Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis were Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 37% to 47% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide gave product peptide having an observed retentiontime of 14.3 minutes. Electrospray Mass Spectrometry (M): calculated3179.6; found 3180.0.

EXAMPLE 51 Preparation of Peptide having SEQ ID NO. 53

[SEQ. ID. NO. 53] His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys GlnLeu Glu Glu Ala Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis were Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 37% to .47% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide gave product peptide having an observed retentiontime of 13.7 minutes. Electrospray Mass Spectrometry (M): calculated3179.6; found 3179.0.

EXAMPLE 52 Preparation of Peptide Having SEQ ID NO. 54

[SEQ. ID. NO. 54] His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Ala Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis were Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 35% to 45% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide gave product peptide having an observed retentiontime of 14.0 minutes. Electrospray Mass Spectrometry (M): calculated3209.6; found 3212.8.

EXAMPLE 53 Preparation of Peptide Having SEQ ID NO. 55

[SEQ. ID. NO. 55] His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Ala Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis were Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 38% to 48% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide gave product peptide having an observed retentiontime of 14.3 minutes. Electrospray Mass Spectrometry (M): calculated3152.5; found 3153.5.

EXAMPLE 54 Preparation of Peptide having SEQ ID NO. 56

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 56] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Ala Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis were Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 35% to 45% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide gave product peptide having an observed retentiontime of 12.1 minutes. Electrospray Mass Spectrometry (M): calculated3195.5; found 3197.7.

EXAMPLE 55 Preparation of Peptide Having SEQ ID NO. 57

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 57] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Ala Phe Leu Lys Asn-NH₂

The above-identified amidated peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis were Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 38% to 48% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide gave product peptide having an observed retentiontime of 10.9 minutes. Electrospray Mass Spectrometry (M): calculated3179.6; found 3180.5.

EXAMPLE 56 Preparation of Peptide Having SEQ ID NO. 58

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 58] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Ala Leu Lys Asn-NH₂

The above-identified amidated peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis were Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 32% to 42% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide gave product peptide having an observed retentiontime of 17.5 minutes. Electrospray Mass Spectrometry (M): calculated3161.5; found 3163.0.

EXAMPLE 57 Preparation of Peptide Having SEQ ID NO. 59

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 59] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Ala Lys Asn-NH₂

The above-identified amidated peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis were Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 32% to 42% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide gave product peptide having an observed retentiontime of 19.5 minutes. Electrospray Mass Spectrometry (M): calculated3195.5; found 3199.

EXAMPLE 58 Preparation of Peptide having SEQ ID NO. 60

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 60] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Ala Asn-NH₂

The above-identified amidated peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis were Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 38% to 48% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide gave product peptide having an observed retentiontime of 14.5 minutes. Electrospray Mass Spectrometry (M): calculated3180.5; found 3183.7.

EXAMPLE 59 Preparation of Peptide Having SEQ ID NO. 61

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 61] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Ala-NH₂

The above-identified amidated peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis were Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 34% to 44% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide gave product peptide having an observed retentiontime of 22.8 minutes. Electrospray Mass Spectrometry (M): calculated3194.6; found 3197.6.

EXAMPLE 60 Preparation of Peptide having SEQ ID NO. 62

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 62] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly ProSer Ser Gly Ala Pro Pro Pro-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated4099.6.

EXAMPLE 61 Preparation of Peptide Having SEQ ID NO. 63

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 63] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly ProSer Ser Gly Ala Pro Pro Pro-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated4042.5.

EXAMPLE 62 Preparation of Peptide having SEQ ID NO. 64

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 64] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly ProSer Ser Gly Ala Pro Pro-NH₂

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated4002.4

EXAMPLE 63 Preparation of Peptide Having SEQ ID NO. 65

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 65] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly ProSer Ser Gly Ala Pro Pro-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3945.4.

EXAMPLE 64 Preparation of Peptide Having SEQ ID NO. 66

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 66] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly ProSer Ser Gly Ala Pro-NH₂

The above-identified amidated peptide is assembled on4-(21-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3905.3.

EXAMPLE 65 Preparation of Peptide Having SEQ ID NO. 67

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 67] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly ProSer Ser Gly Ala Pro-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3848.2.

EXAMPLE 66 Preparation of Peptide Having SEQ ID NO. 68

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 68] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly ProSer Ser Gly Ala-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3808.2.

EXAMPLE 67 Preparation of Peptide Having SEQ ID NO. 69

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 69] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly ProSer Ser Gly Ala-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3751.1.

EXAMPLE 68 Preparation of Peptide Having SEQ ID NO. 70

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 70] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly ProSer Ser Gly-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3737.1.

EXAMPLE 69 Preparation of Peptide Having SEQ ID NO. 71

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 71] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly ProSer Ser Gly-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3680.1.

EXAMPLE 70 Preparation of Peptide Having SEQ ID NO. 72

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 72] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly ProSer Ser-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3680.1

EXAMPLE 71 Preparation of Peptide Having SEQ ID NO. 73

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 73] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly ProSer Ser-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3623.0.

EXAMPLE 72 Preparation of Peptide Having SEQ ID NO. 74

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 74] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly ProSer- NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3593.0

EXAMPLE 73 Preparation of Peptide Having SEQ ID NO. 75

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 75] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly ProSer- NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3535.9

EXAMPLE 74 Preparation of Peptide Having SEQ ID NO. 76

[SEQ. ID. NO. 76] His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly GlyPro-NH₂

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3505.9.

EXAMPLE 75 Preparation of Peptide Having SEQ ID NO. 77

[SEQ. ID. NO. 77] His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly GlyPro-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3448.8.

EXAMPLE 76 Preparation of Peptide Having SEQ ID NO. 78

[SEQ. ID. NO. 78] His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly-NH₂

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3351.7.

EXAMPLE 77 Preparation of Peptide Having SEQ ID NO. 79

[SEQ. ID. NO. 79] His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly-NH₂

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3351.8.

EXAMPLE 78 Preparation of Peptide Having SEQ ID NO. 80

[SEQ. ID. NO. 80] His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3294.7.

EXAMPLE 79 Preparation of Peptide Having SEQ ID NO. 81

[SEQ. ID. NO. 81] His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly tProSer Ser Gly Ala tPro tPro tPro-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Double couplings are requiredat residues 37,36 and 31. Used in analysis are Solvent A (0.1% TFA inwater) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30%to 60% Solvent B in Solvent A over 30 minutes) of the lyophilizedpeptide is then carried out to determine the retention time of theproduct peptide. Electrospray Mass Spectrometry (M): calculated 4197.1.

EXAMPLE 80 Preparation of Peptide Having SEQ ID NO. 82

[SEQ. ID. NO. 82] His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly ProSer Ser Gly Ala tPro tPro tPro-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Double couplings are requiredat residues 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA inwater) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30%to 60% Solvent B in Solvent A over 30 minutes) of the lyophilizedpeptide is then carried out to determine the retention time of theproduct peptide. Electrospray Mass Spectrometry (M): calculated 4179.1.

EXAMPLE 81 Preparation of Peptide Having SEQ ID NO. 83

[SEQ. ID. NO. 83] His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly GlyNMeala Ser Ser Gly Ala Pro Pro-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Double couplings are requiredat residues 36 and 31. Used in analysis are Solvent A (0.1% TFA inwater) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30%to 60% Solvent B in Solvent A over 30 minutes) of the lyophilizedpeptide is then carried out to determine the retention time of theproduct peptide. Electrospray Mass Spectrometry (M): calculated 3948.3.

EXAMPLE 82 Preparation of Peptide Having SEQ ID NO. 84

[SEQ. ID. NO. 84] His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly GlyNMeala Ser Ser Gly Ala NMeala Nmeala-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Double couplings are requiredat residues 36 and 31. Used in analysis are Solvent A (0.1% TFA inwater) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30%to 60% Solvent B in Solvent A over 30 minutes) of the lyophilizedpeptide is then carried out to determine the retention time of theproduct peptide. Electrospray Mass Spectrometry (M): calculated 3840.1.

EXAMPLE 83 Preparation of Peptide Having SEQ ID NO. 85

[SEQ. ID. NO. 85] His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly hProSer Ser Gly Ala hPro hPro-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Double couplings are requiredat residues 36 and 31. Used in analysis are Solvent A (0.1% TFA inwater) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30%to 60% Solvent B in Solvent A over 30 minutes) of the lyophilizedpeptide is then carried out to determine the retention time of theproduct peptide. Electrospray Mass Spectrometry (M): calculated 4050.1.

EXAMPLE 84 Preparation of Peptide Having SEQ ID NO. 86

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 86] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly hProSer Ser Gly Ala hPro-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. A double coupling is requiredat residue 31. Used in analysis are Solvent A (0.1% TFA in water) andSolvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%Solvent B in Solvent A over 30 minutes) of the lyophilized peptide isthen carried out to determine the retention time of the product peptide.Electrospray Mass Spectrometry (M): calculated 3937.1

EXAMPLE 85 Preparation of Peptide having SEQ ID NO. 87

Arg Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 87] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly ProSer Ser Gly Ala-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3827.2.

EXAMPLE 86 Preparation of Peptide having SEQ ID NO. 88

His Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 88] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes). of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3394.8.

EXAMPLE 87 Preparation of Peptide Having SEQ ID NO. 89

His Gly Glu Gly Thr Naphthylala [SEQ. ID. NO. 89] Thr Ser Asp Leu SerLys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3289.5.

EXAMPLE 88 Preparation of Peptide Having SEQ ID NO. 90

His Gly Glu Gly Thr Phe Ser Ser [SEQ. ID. NO. 90] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3280.7.

EXAMPLE 89 Preparation of Peptide Having SEQ ID NO. 91

His Gly Glu Gly Thr Phe Ser Thr [SEQ. ID. NO. 91] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3294.7.

EXAMPLE 90 Preparation of Peptide Having SEQ ID NO. 92

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 92] Glu Leu Ser Lys GlnMet Ala Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3250.7.

EXAMPLE 91 Preparation of Peptide having SEQ ID NO. 93

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 93] Asp pentylgly Ser LysGln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3253.5.

EXAMPLE 92 Preparation of Peptide Having SEQ ID NO. 94

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 94] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Naphthylala Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3289.5.

EXAMPLE 93 Preparation of Peptide Having SEQ ID NO. 95

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 95] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe tButylgly Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3183.4.

EXAMPLE 94 Preparation of Peptide Having SEQ ID NO. 96

[SEQ. ID. NO. 96] His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Asp Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3237.6.

EXAMPLE 95 Preparation of Peptide having SEQ ID NO. 97

[SEQ. ID. NO. 97] His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly ProSer Ser-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3637.9.

EXAMPLE 96 Preparation of Peptide Having SEQ ID NO. 98

[SEQ. ID. NO. 98] His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3309.7.

EXAMPLE 97 Preparation of Peptide having SEQ ID NO. 99

[SEQ. ID. NO. 99] His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Tie Glu Trp Leu Lys Asn Gly Gly hProSer Ser Gly Ala hPro hPro-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Ecample 37. Double couplings are requiredat residues 36 and 31. Used in analysis are Solvent A (0.1% TFA inwater) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30%to 60% Solvent B in Solvent A over 30 minutes) of the lyophilizedpeptide is then carried out to determine the retention time of theproduct peptide. Electrospray Mass Spectrometry (M): calculated 3711.1.

EXAMPLE 98 Preparation of C-Terminal Carboxylic Acid PeptidesCorresponding to the Above C-Terminal Amide Sequences for SEQ ID NOS. 7,40-61, 68-75, 78-80 and 87-96

Peptides having the sequences of SEQ ID NOS. 7, 40-61, 68-75, 78-80 and87-96 are assembled on the so called Wang resin (p-alkoxybenzylalacoholresin (Bachem, 0.54 mmole/g)) using Fmoc-protected amino acids (AppliedBiosystems, Inc.), cleaved from the resin, deprotected and purified in asimilar way to Example 37. Used in analysis are Solvent A (0.1% TFA inwater) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30%to 60% Solvent B in Solvent A over 30 minutes) of the lyophilizedpeptide is then carried out to determine the retention time of theproduct peptide. Electrospray Mass Spectrometry provides anexperimentally determined (M).

EXAMPLE 99 Preparation of C-Terminal Carboxylic Acid PeptidesCorresponding to the Above C-Terminal Amide Sequences for SEQ ID NOS.62-67, 76, 77 and 81-86

Peptides having the sequences of SEQ ID NOS. 62-67, 76, 77 and 81-86 areassembled on the 2-chlorotritylchloride resin (200-400 mesh), 2% DVB(Novabiochem, 0.4-1.0 mmole/g)) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 37. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry provides anexperimentally determined (M).

EXAMPLE 100 Preparation of Peptide Having SEQ ID NO. 100

[SEQ. ID. NO. 100] Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above amidated peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.). In general, single-coupling cycles were usedthroughout the synthesis and Fast Moc (HBTU activation) chemistry wasemployed. Deprotection (Fmoc group removal)of the growing peptide chainwas achieved using piperidine. Final deprotection of the completedpeptide resin was achieved using a mixture of triethylsilane (0.2 mL),ethanedithiol (0.2 mL), anisole (0.2 mL), water (0.2 mL) andtrifluoroacetic acid (15 mL) according to standard methods (Introductionto Cleavage Techniques, Applied Biosystems, Inc.) The peptide wasprecipitated in ether/water (50 mL) and centrifuged. The precipitate wasreconstituted in glacial acetic acid and lyophilized. The lyophilizedpeptide was dissolved in water). Crude purity was about 75%.

Used in purification steps and analysis were Solvent A (0.1% TFA inwater) and Solvent B (0.1% TFA in ACN).

The solution containing peptide was applied to a preparative C-18 columnand purified (10% to 40% Solvent B in Solvent A over 40 minutes). Purityof fractions was determined isocratically using a C-18 analyticalcolumn. Pure fractions were pooled furnishing the above-identifiedpeptide. Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent Aover 30 minutes) of the lyophilized peptide gave product peptide havingan observed retention time of 19.2 minutes. Electrospray MassSpectrometry (M): calculated 3171.6; found 3172.

EXAMPLE 101 Preparation of Peptide Having SEQ ID NO. 101

[SEQ. ID. NO. 101] His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above amidated peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis were SolventA (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). AnalyticalRP-HPLC (gradient 36% to 46% Solvent B in Solvent A over 30 minutes) ofthe lyophilized peptide gave product peptide having an observedretention time of 14.9 minutes. Electrospray Mass Spectrometry (M):calculated 3179.6; found 3180.

EXAMPLE 102 Preparation of Peptide Having SEQ ID NO. 102

[SEQ. ID. NO. 102] His Gly Glu Ala Thr Phe Thr Ser Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above amidated peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis were SolventA (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). AnalyticalRP-HPLC (gradient 37% to 47% Solvent B in Solvent A over 30 minutes) ofthe lyophilized peptide gave product peptide having an observedretention time of 12.2 minutes. Electrospray Mass Spectrometry (M):calculated 3251.6; found 3253.3.

EXAMPLE 103 Preparation of Peptide Having SEQ ID NO. 103

[SEQ. ID. NO. 103] His Gly Glu Gly Thr Phe Thr Ser Ala Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above amidated peptide was assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis were SolventA (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). AnalyticalRP-HPLC (gradient 35% to 45% Solvent B in Solvent A over 30 minutes) ofthe lyophilized peptide gave product peptide having an observedretention time of 16.3 minutes. Electrospray Mass Spectrometry (M):calculated 3193.6; found 3197.

EXAMPLE 104 Preparation of Peptide Having SEQ ID NO. 104

[SEQ. ID. NO. 104] Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3228.6.

EXAMPLE 105 Preparation of Peptide Having SEQ ID NO. 105

[SEQ. ID. NO. 105] His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3234.7.

EXAMPLE 106 Preparation of Peptide having SEQ ID NO. 106

[SEQ. ID. NO. 106] His Gly Glu Ala Thr Phe Thr Ser Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3308.7.

EXAMPLE 107 Preparation of Peptide Having SEQ ID NO. 107

[SEQ. ID. NO. 107] His Gly Glu Gly Thr Phe Thr Ser Ala Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3250.7

EXAMPLE 108 Preparation of Peptide Having SEQ ID NO. 108

[SEQ. ID. NO. 108] His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3252.6.

EXAMPLE 109 Preparation of Peptide Having SEQ ID NO. 109

[SEQ. ID. NO. 109] Ala Ala Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3200.6.

EXAMPLE 110 Preparation of Peptide Having SEQ ID NO. 110

[SEQ. ID. NO. 110] Ala Ala Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl) -Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3143.5.

EXAMPLE 111 Preparation of Peptide Having SEQ ID NO. 111

[SEQ. ID. NO. 111] Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3214.6.

EXAMPLE 112 Preparation of Peptide Having SEQ ID NO. 112

[SEQ. ID. NO. 112] Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3157.5.

EXAMPLE 113 Preparation of Peptide Having SEQ ID NO. 113

[SEQ. ID. NO. 113] Ala Gly Asp Gly Ala Phe Thr Ser Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3184.6.

EXAMPLE 114 Preparation of Peptide Having SEQ ID NO. 114

[SEQ. ID. NO. 114] Ala Gly Asp Gly Ala Phe Thr Ser Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3127.5.

EXAMPLE 115 Preparation of Peptide Having SEQ ID NO. 115

[SEQ. ID. NO. 115] Ala Gly Asp Gly Thr NaphthylAla Thr Ser Asp Leu SerLys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3266.4.

EXAMPLE 116 Preparation of Peptide Having SEQ ID NO. 116

Ala Gly Asp Gly Thr Naphthylala [SEQ. ID. NO. 116] Thr Ser Asp Leu SerLys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3209.4.

EXAMPLE 117 Preparation of Peptide Having SEQ ID NO. 117

Ala Gly Asp Gly Thr Phe Ser Ser [SEQ. ID. NO. 117] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3200.6.

EXAMPLE 118 Preparation of Peptide Having SEQ ID NO. 118

Ala Gly Asp Gly Thr Phe Ser Ser [SEQ. ID. NO. 118] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3143.5.

EXAMPLE 119 Preparation of Peptide Having SEQ ID NO. 119

Ala Gly Asp Gly Thr Phe Thr Ala [SEQ. ID. NO. 119] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3198.6.

EXAMPLE 120 Preparation of Peptide Having SEQ ID NO. 120

Ala Gly Asp Gly Thr Phe Thr Ala [SEQ. ID. NO. 120] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3141.5.

EXAMPLE 121 Preparation of Peptide Having SEQ ID NO. 121

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 121] Ala Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3170.6.

EXAMPLE 122 Preparation of Peptide Having SEQ ID NO. 122

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 122] Ala Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3113.5.

EXAMPLE 123 Preparation of Peptide Having SEQ ID NO. 123

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 123] Glu Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3228.6.

EXAMPLE 124 Preparation of Peptide Having SEQ ID NO. 124

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 124] Glu Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3171.6.

EXAMPLE 125 Preparation of Peptide Having SEQ ID NO. 125

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 125] Asp Ala Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3172.5.

EXAMPLE 126 Preparation of Peptide Having SEQ ID NO. 126

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 126] Asp Ala Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptiden is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3115.4.

EXAMPLE 127 Preparation of Peptide Having SEQ ID NO. 127

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 127] Asp Pentylgly Ser LysGln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3230.4.

EXAMPLE 128 Preparation of Peptide Having SEQ ID NO. 128

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 128] Asp Pentylgly Ser LysGln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3198.6.

EXAMPLE 129 Preparation of Peptide Having SEQ ID NO. 129

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 129] Asp Leu Ala Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3141.5.

EXAMPLE 130 Preparation of Peptide Having SEQ ID NO. 130

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 130] Asp Leu Ala Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3157.5.

EXAMPLE 131 Preparation of Peptide Having SEQ ID NO. 131

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 131] Asp Leu Ser Ala GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3100.4.

EXAMPLE 132 Preparation of Peptide Having SEQ ID NO. 132

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 132] Asp Leu Ser Ala GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3157.6.

EXAMPLE 133 Preparation of Peptide Having SEQ ID NO. 133

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 133] Asp Leu Ser Lys AlaMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3100.5.

EXAMPLE 134 Preparation of Peptide Having SEQ ID NO. 134

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 134] Asp Leu Ser Lys AlaLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3100.5.

EXAMPLE 135 Preparation of Peptide Having SEQ ID NO. 135

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 135] Asp Leu Ser Lys GlnAla Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3154.5.

EXAMPLE 136 Preparation of Peptide Having SEQ ID NO. 136

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 136] Asp Leu Ser Lys GlnAla Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3115.5.

EXAMPLE 137 Preparation of Peptide Having SEQ ID NO. 137

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 137] Asp Leu Ser Lys GlnPentylgly Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3212.4.

EXAMPLE 138 Preparation of Peptide Having SEQ ID NO. 138

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 138] Asp Leu Ser Lys GlnPentylgly Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3173.4.

EXAMPLE 139 Preparation of Peptide Having SEQ ID NO. 139

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 139] Asp Leu Ser Lys GlnMet Ala Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3156.6.

EXAMPLE 140 Preparation of Peptide Having SEQ ID NO. 140

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 140] Asp Leu Ser Lys GlnLeu Ala Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3099.5.

EXAMPLE 141 Preparation of Peptide Having SEQ ID NO. 141

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 141] Asp Leu Ser Lys GlnMet Glu Ala Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3156.6.

EXAMPLE 142 Preparation of Peptide Having SEQ ID NO. 142

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 142] Asp Leu Ser Lys GlnLeu Glu Ala Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3099.5.

EXAMPLE 143 Preparation of Peptide Having SEQ ID NO. 143

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 143] Asp Leu Ser Lys GlnMet Glu Glu Ala Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3156.6.

EXAMPLE 144 Preparation of Peptide Having SEQ ID NO. 144

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 144] Asp Leu Ser Lys GlnLeu Glu Glu Ala Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3099.5.

EXAMPLE 145 Preparation of Peptide Having SEQ ID NO. 145

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 145] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Ala Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3186.6.

EXAMPLE 146 Preparation of Peptide Having SEQ ID NO. 146

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 146] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Ala Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3129.5.

EXAMPLE 147 Preparation of Peptide Having SEQ ID NO. 147

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 147] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Ala Leu Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3129.5.

EXAMPLE 148 Preparation of Peptide Having SEQ ID NO. 148

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 148] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Ala Leu Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3072.4.

EXAMPLE 149 Preparation of Peptide Having SEQ ID NO. 149

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 149] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Ala Phe Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3172.5.

EXAMPLE 150 Preparation of Peptide Having SEQ ID NO. 150

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 150] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Ala Phe Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3115.5.

EXAMPLE 151 Preparation of Peptide Having SEQ ID NO. 151

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 151] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Naphthylala Ile Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3266.4.

EXAMPLE 152 Preparation of Peptide Having SEQ ID NO. 152

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 152] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Naphthylala Ile Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3209.4.

EXAMPLE 153 Preparation of Peptide Having SEQ ID NO. 153

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 153] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Val Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3200.6.

EXAMPLE 154 Preparation of Peptide Having SEQ ID NO. 154

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 154] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Val Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3143.5.

EXAMPLE 155 Preparation of Peptide Having SEQ ID NO. 155

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 155] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe tButylgly Glu Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3216.5.

EXAMPLE 156 Preparation of Peptide Having SEQ ID NO. 156

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 156] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe tButylgly Glu Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3159.4.

EXAMPLE 157 Preparation of Peptide Having SEQ ID NO. 157

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 157] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Asp Trp Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3200.6.

EXAMPLE 158 Preparation of Peptide Having SEQ ID NO. 158

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 158] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Asp Phe Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3143.5.

EXAMPLE 159 Preparation of Peptide Having SEQ ID NO. 159

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 159] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Ala Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3099.5.

EXAMPLE 160 Preparation of Peptide Having SEQ ID NO. 160

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 160] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Ala Leu Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3081.4.

EXAMPLE 161 Preparation of Peptide Having SEQ ID NO. 161

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 161] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Ala Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3172.5.

EXAMPLE 162 Preparation of Peptide Having SEQ ID NO. 162

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 162] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Ala Lys Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3115.5.

EXAMPLE 163 Preparation of Peptide Having SEQ ID NO. 163

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 163] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Ala Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3157.5.

EXAMPLE 164 Preparation of Peptide Having SEQ ID NO. 164

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 164] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Ala Asn-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3100.4.

EXAMPLE 165 Preparation of Peptide Having SEQ ID NO. 165

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 165] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Ala-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3171.6.

EXAMPLE 166 Preparation of Peptide Having SEQ ID NO. 166

Ala Gly Asp Gly Thr Phe Thr Ser [SEQ. ID. NO. 166] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Ala-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3114.5.

EXAMPLE 167 Preparation of Peptide Having SEQ ID NO. 167

Ala Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 167] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly ProSer Ser Gly Ala Pro Pro Pro-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated4033.5.

EXAMPLE 168 Preparation of Peptide Having SEQ ID NO. 168

His Gly Ala Gly Thr Phe Thr Ser [SEQ. ID. NO. 168] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly ProSer Ser Gly Ala Pro Pro Pro-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3984.4.

EXAMPLE 169 Preparation of Peptide Having SEQ ID NO. 169

His Gly Glu Ala Thr Phe Thr Ser [SEQ. ID. NO. 169] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly ProSer Ser Gly Ala Pro Pro-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated4016.5.

EXAMPLE 170 Preparation of Peptide Having SEQ ID NO. 170

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 170] Ala Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly ProSer Ser Gly Ala Pro-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3861.3.

EXAMPLE 171 Preparation of Peptide Having SEQ ID NO. 171

Ala Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 171] Asp Ala Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly ProSer Ser Gly Ala Pro-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3746.1.

EXAMPLE 172 Preparation of Peptide Having SEQ ID NO. 172

Ala Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 172] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly ProSer Ser Gly Ala-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3742.1.

EXAMPLE 173 Preparation of Peptide having SEQ ID NO. 173

His Gly Ala Gly Thr Phe Thr Ser [SEQ. ID. NO. 173] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly ProSer Ser Gly Ala-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3693.1.

EXAMPLE 174 Preparation of Peptide Having SEQ ID NO. 174

His Gly Glu Ala Thr Phe Thr Ser [SEQ. ID. NO. 174] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly ProSer Ser Gly-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3751.2.

EXAMPLE 175 Preparation of Peptide Having SEQ ID NO. 175

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 175] Ala Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly ProSer Ser-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3634.1.

EXAMPLE 176 Preparation of Peptide Having SEQ ID NO. 176

Ala Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 176] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly ProSer-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3526.9.

EXAMPLE 177 Preparation of Peptide Having SEQ ID NO. 177

His Gly Ala Gly Thr Phe Thr Ser [SEQ. ID. NO. 177] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly ProSer-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3477.9.

EXAMPLE 178 Preparation of Peptide Having SEQ ID NO. 178

His Gly Glu Ala Thr Phe Thr Ser [SEQ. ID. NO. 178] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly GlyPro-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3519.9.

EXAMPLE 179 Preparation of Peptide Having SEQ ID NO. 179

His Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 179] Ala Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3307.7.

EXAMPLE 180 Preparation of Peptide Having SEQ ID NO. 180

Ala Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 180] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3186.5.

EXAMPLE 181 Preparation of Peptide Having SEQ ID NO. 181

His Gly Ala Gly Thr Phe Thr Ser [SEQ. ID. NO. 181] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly tProSer Ser Gly Ala tPro tPro tPro-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Double couplings are requiredat residues 37,36 and 31. Used in analysis are Solvent A (0.1% TFA inwater) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30%to 60% Solvent B in Solvent A over 30 minutes) of the lyophilizedpeptide is then carried out to determine the retention time of theproduct peptide. Electrospray Mass Spectrometry (M): calculated 4121.1.

EXAMPLE 182 Preparation of Peptide Having SEQ ID NO. 182

His Gly Glu Ala Thr Phe Thr Ser [SEQ. ID. NO. 182] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly ProSer Ser Gly Ala tPro tPro tPro-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Double couplings are requiredat residues 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA inwater) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30%to 60% Solvent B in Solvent A over 30 minutes) of the lyophilizedpeptide is then carried out to determine the retention time of theproduct peptide. Electrospray Mass Spectrometry (M): calculated 4173.2.

EXAMPLE 183

Preparation of Peptide Having SEQ ID NO. 183 His Gly Glu Gly Thr Phe ThrSer [SEQ. ID. NO. 183] Ala Leu Ser Lys Gln Met Glu Glu Glu Ala Val ArgLeu Phe Ile Glu Trp Leu Lys Asn Gly Gly NMeala Ser Ser Gly Ala NMealaNMeala-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Compound 1. Double couplings are requiredat residues 36 and 31. Used in analysis are Solvent A (0.1% TFA inwater) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30%to 60% Solvent B in Solvent A over 30 minutes) of the lyophilizedpeptide is then carried out to determine the retention time of theproduct peptide. Electrospray Mass Spectrometry (M): calculated 3796.1.

EXAMPLE 184 Preparation of Peptide Having SEQ ID NO. 184

Ala Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 184] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly hProSer Ser Gly Ala hPro-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. A double coupling is requiredat residue 31. Used in analysis are Solvent A (0.1% TFA in water) andSolvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%Solvent B in Solvent A over 30 minutes) of the lyophilized peptide isthen carried out to determine the retention time of the product peptide.Electrospray Mass Spectrometry (M): calculated 3871.1.

EXAMPLE 185 Preparation of Peptide Having SEQ ID NO. 185

His Gly Ala Gly Thr Phe Thr Ser [SEQ. ID. NO. 185] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly ProSer Ser Gly Ala-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3750.2.

EXAMPLE 186 Preparation of Peptide Having SEQ ID NO. 186

His Gly Asp Ala Thr Phe Thr Ser [SEQ. ID. NO. 186] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly-NH₂

The above-identified amdiated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated3408.8.

EXAMPLE 187 Preparation of Peptide Having SEQ ID NO. 187

Ala Gly Glu Gly Thr Phe Thr Ser [SEQ. ID. NO. 187] Asp Leu Ser Lys GlnMet Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly ProSer Ser Gly Ala Pro Pro Pro Ser-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated4120.6.

EXAMPLE 188 Preparation of Peptide Having SEQ ID NO. 188

Ala Gly Ala Gly Thr Phe Thr Ser [SEQ. ID. NO. 188] Asp Leu Ser Lys GlnLeu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly ProSer Ser Gly Ala Pro Pro Pro Ser-NH₂

The above-identified amidated peptide is assembled on4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucineMBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids(Applied Biosystems, Inc.), cleaved from the resin, deprotected andpurified in a similar way to Example 100. Used in analysis are Solvent A(0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC(gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of thelyophilized peptide is then carried out to determine the retention timeof the product peptide. Electrospray Mass Spectrometry (M): calculated4005.5.

EXAMPLE 189 Preparation of C-Terminal Carboxylic Acid PeptidesCorresponding to the Above C-Terminal Amide Sequences for PeptidesHaving SEQ ID NOS. 100-166. 172-177. 179-180 and 185-188

C-terminal carboxylic acid peptides corresponding to amidated having SEQID NOS. 100-166, 172-177, 179-180 and 185-188 are assembled on the socalled Wang resin (p-alkoxybenzylalacohol resin (Bachem, 0.54 mmole/g))using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleavedfrom the resin, deprotected and purified in a similar way to thatdescribed in Example 100. Used in analysis are Solvent A (0.1% TFA inwater) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30%to 60% Solvent B in Solvent A over 30 minutes) of the lyophilizedpeptide is then carried out to determine the retention time of theproduct peptide. Electrospray Mass Spectrometry provides anexperimentally determined (M).

EXAMPLE 190 Preparation of C-Terminal Carboxylic Acid PeptidesCorresponding to the Above C-Terminal Amide Sequences for PeptidesHaving SEQ ID NOS. 167-171, 178 and 181-184

C-terminal carboxylic acid eptides corresponding to amidated SEQ ID NOS.167-171, 178 and 181-184 are assembled on the 2-chlorotritylchlorideresin (200-400 mesh), 2% DVB (Novabiochem, 0.4-1.0 mmole/g)) usingFmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from theresin, deprotected and purified in a similar way to that described inExample 100. Used in analysis are Solvent A (0.1% TFA in water) andSolvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60%Solvent B in Solvent A over 30 minutes) of the lyophilized peptide isthen carried out to determine the retention time of the product peptide.Electrospray Mass Spectrometry provides an experimentally determined(M).

Various modifications of the invention in addition to those shown anddescribed herein will become apparent to those skilled in the art fromthe foregoing description and fall within the scope of the followingclaims.

1-31. (canceled)
 32. A pharmaceutical composition comprising anexendin-4 and a buffer, wherein said composition has a pH of from about3.0 to about 8.0.
 33. The composition of claim 32, wherein said pH isfrom about 5.6 to about 7.4.
 34. The composition of claim 32, whereinsaid pH is from about 3.5 to about
 5. 35. The composition of claim 32,wherein said pH is about 4.5.
 36. The composition of claim 32, furthercomprising an exendin-3.
 37. The composition of claim 32, wherein saidbuffer comprises an acetate buffer.
 38. The composition of claim 32,further comprising an isotonicity agent.
 39. The composition of claim38, wherein said isotonicity agent is selected from the group consistingof sodium chloride, dextrose, boric acid, sodium tartrate, propyleneglycol, polyols, and any combination thereof.
 40. The composition ofclaim 32, further comprising a pharmaceutically acceptable carrier orexcipient selected from the group consisting of calcium carbonate,calcium phosphate, lactose, glucose, sucrose, starch, cellulosederivatives, gelatin, oils, polyethylene glycol, and any combinationthereof.
 41. The composition of claim 32, further comprising at leastone additional substance other than an exendin that reduces food intake,appetite, body weight, obesity or any combination thereof.
 42. Thecomposition of claim 41, wherein said at least one additional substanceis selected from the group consisting of amylin, an amylin agonist, aleptin, a cholecystokinin (CCK), CCK-8, a calcitonin, and anycombination thereof.
 43. The composition of claim 41, wherein said atleast one additional substance comprises ^(25,28,29) Pro human amylin.44. The composition of claim 32, wherein said composition is formulatedto provide a daily dose of from about 0.1 μg/kg to about 100 μg/kg ofsaid exendin in a single or divided dose.
 45. The composition of claim32, wherein said composition is formulated to provide a daily dose offrom about 0.1 μg/kg to about 10 μg/kg of said exendin in a single ordivided dose.
 46. The composition of claim 32, wherein said compositionis formulated to provide a daily dose of from about 0.1 μg/kg to about 1μg/kg of said exendin in a single or divided dose.
 47. The compositionof claim 32, wherein said composition is formulated to provide a dailydose of from about 0.01 mg to about 5 mg of said exendin in a single ordivided dose.
 48. The composition of claim 32, wherein said compositionis formulated to provide a daily dose of from about 0.01 mg to about 2mg of said exendin in a single or divided dose.
 49. The composition ofclaim 32, wherein said composition is formulated to provide a daily doseof from about 0.01 mg to about 1 mg of said exendin in a single ordivided dose.
 50. The composition of claim 32, wherein said compositionis formulated to provide a daily dose of from about 0.01 mg to about 0.5mg of said exendin in a single or divided dose.
 51. The composition ofclaim 32, wherein said composition is formulated for intravenous,intraperitoneal, subcutaneous, intramuscular, oral, topical,transmucosal or pulmonary administration.
 52. A pharmaceuticalcomposition comprising exendin-4, mannitol, and an acetate buffer,wherein said composition has a pH of about 4.5.
 53. The composition ofclaim 52, wherein said composition is formulated to provide a daily doseof from about 0.1 μg/kg to about 1 μg/kg of said exendin-4 in a singleor divided dose.
 54. The composition of claim 52, wherein saidcomposition is formulated to provide a daily dose of from about 0.01 mgto about 0.5 mg of said exendin-4 in a single or divided dose.
 55. Thecomposition of claim 52, further comprising at least one additionalsubstance other than an exendin that reduces food intake, appetite, bodyweight, obesity or any combination thereof.
 56. A pharmaceuticalcomposition comprising an exendin-3 and a buffer, wherein saidcomposition has a pH of from about 3.0 to about 8.0.
 57. The compositionof claim 56, wherein said pH is from about 3.5 to about
 5. 58. Thecomposition of claim 56, wherein said buffer comprises an acetatebuffer.
 59. The composition of claim 56, further comprising anisotonicity agent.
 60. The composition of claim 56, wherein saidisotonicity agent is selected from the group consisting of sodiumchloride, dextrose, boric acid, sodium tartrate, propylene glycol,polyols, and any combination thereof.
 61. The composition of claim 56,further comprising a pharmaceutically acceptable carrier or excipientselected from the group consisting of calcium carbonate, calciumphosphate, lactose, glucose, sucrose, starch, cellulose derivatives,gelatin, oils, polyethylene glycol, and any combination thereof.
 62. Thecomposition of claim 56, further comprising at least one additionalsubstance other than an exendin that reduces food intake, appetite, bodyweight, obesity or any combination thereof.
 63. The composition of claim62, wherein said at least one additional substance is selected from thegroup consisting of amylin, an amylin agonist, a leptin, acholecystokinin (CCK), CCK-8, a calcitonin, and any combination thereof.64. The composition of claim 62, wherein said at least one additionalsubstance comprises ^(25,28,29) Pro human amylin.
 65. The composition ofclaim 56, wherein said composition is formulated to provide a daily doseof from about 0.1 μg/kg to about 100 μg/kg of said exendin in a singleor divided dose.
 66. The composition of claim 56, wherein saidcomposition is formulated to provide a daily dose of from about 0.1μg/kg to about 10 μg/kg of said exendin in a single or divided dose. 67.The composition of claim 56, wherein said composition is formulated toprovide a daily dose of from about 0.1 μg/kg to about 1 μg/kg of saidexendin in a single or divided dose.
 68. The composition of claim 56,wherein said composition is formulated to provide a daily dose of fromabout 0.01 mg to about 5 mg of said exendin in a single or divided dose.69. The composition of claim 56, wherein said composition is formulatedto provide a daily dose of from about 0.01 mg to about 0.5 mg of saidexendin in a single or divided dose.
 70. The composition of claim 56,wherein said composition is formulated for intravenous, intraperitoneal,subcutaneous, intramuscular, oral, topical, transmucosal or pulmonaryadministration.
 71. A pharmaceutical composition comprising an exendinselected from the group consisting of exendin-4 (1-30), exendin-4 (1-30)amide, exendin-4 (1-28) amide, ¹⁴Leu, ²⁵Phe exendin-4 amide, ⁴Leu, ²⁵Pheexendin-4 (1-28) amide, ¹⁴Leu, ²²Ala, ²⁵Phe exendin-4 (1-28) amide, andany combination thereof; and a buffer, wherein said composition has a pHof from about 3.0 to about 8.0.